<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Neurosci.</journal-id>
<journal-title>Frontiers in Neuroscience</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Neurosci.</abbrev-journal-title>
<issn pub-type="epub">1662-453X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fnins.2024.1270041</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neuroscience</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title><sup>1</sup>H-NMR metabolomics investigation of CSF from children with HIV reveals altered neuroenergetics due to persistent immune activation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Thirion</surname> <given-names>Anicia</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2525396/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Loots</surname> <given-names>Du Toit</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1311455/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Williams</surname> <given-names>Monray E.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1028278/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Solomons</surname> <given-names>Regan</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/471340/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Mason</surname> <given-names>Shayne</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/383089/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Biochemistry, Human Metabolomics, Faculty of Natural and Agricultural Sciences, North-West University</institution>, <addr-line>Potchefstroom</addr-line>, <country>South Africa</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Pediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University</institution>, <addr-line>Tygerberg</addr-line>, <country>South Africa</country></aff>
<author-notes>
<fn fn-type="edited-by" id="fn0001">
<p>Edited by: Marcos Batista Machado, Federal University of Amazonas, Brazil</p>
</fn>
<fn fn-type="edited-by" id="fn0002">
<p>Reviewed by: Mayur Doke, University of Miami Health System, United States</p>
<p>Kim M. Cecil, Cincinnati Children's Hospital Medical Center, United States</p>
</fn>
<corresp id="c001">&#x002A;Correspondence: Shayne Mason, <email>nmr.nwu@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>30</day>
<month>04</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>18</volume>
<elocation-id>1270041</elocation-id>
<history>
<date date-type="received">
<day>31</day>
<month>07</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>15</day>
<month>04</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2024 Thirion, Loots, Williams, Solomons and Mason.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Thirion, Loots, Williams, Solomons and Mason</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec id="sec1">
<title>Background</title>
<p>HIV can invade the central nervous system (CNS) early during infection, invading perivascular macrophages and microglia, which, in turn, release viral particles and immune mediators that dysregulate all brain cell types. Consequently, children living with HIV often present with neurodevelopmental delays.</p>
</sec>
<sec id="sec2">
<title>Methods</title>
<p>In this study, we used proton nuclear magnetic resonance (<sup>1</sup>H-NMR) spectroscopy to analyze the neurometabolic profile of HIV infection using cerebrospinal fluid samples obtained from 17 HIV+ and 50 HIV&#x2212; South African children.</p>
</sec>
<sec id="sec3">
<title>Results</title>
<p>Nine metabolites, including glucose, lactate, glutamine, 1,2-propanediol, acetone, 3-hydroxybutyrate, acetoacetate, 2-hydroxybutyrate, and myo-inositol, showed significant differences when comparing children infected with HIV and those uninfected. These metabolites may be associated with activation of the innate immune response and disruption of neuroenergetics pathways.</p>
</sec>
<sec id="sec4">
<title>Conclusion</title>
<p>These results elucidate the neurometabolic state of children infected with HIV, including upregulation of glycolysis, dysregulation of ketone body metabolism, and elevated reactive oxygen species production. Furthermore, we hypothesize that neuroinflammation alters astrocyte&#x2013;neuron communication, lowering neuronal activity in children infected with HIV, which may contribute to the neurodevelopmental delay often observed in this population.</p>
</sec>
</abstract>
<kwd-group>
<kwd>pediatric</kwd>
<kwd>human immunodeficiency virus (HIV)</kwd>
<kwd>cerebrospinal fluid (CSF)</kwd>
<kwd>HIV-associated neurocognitive disorder (HAND)</kwd>
<kwd>proton nuclear magnetic resonance (<sup>1</sup>H-NMR)</kwd>
<kwd>metabolomics</kwd>
<kwd>neuroenergetics</kwd>
</kwd-group>
<contract-num rid="cn1">TTK22031652</contract-num>
<contract-num rid="cn2">23/84</contract-num>
<contract-sponsor id="cn1">NRF Thuthuka</contract-sponsor>
<contract-sponsor id="cn2">Poliomyelitis Research Foundation (PRF)<named-content content-type="fundref-id">10.13039/501100001323</named-content></contract-sponsor>
<counts>
<fig-count count="3"/>
<table-count count="3"/>
<equation-count count="0"/>
<ref-count count="59"/>
<page-count count="14"/>
<word-count count="9959"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Neuroenergetics and Brain Health</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="sec5">
<label>1</label>
<title>Introduction</title>
<p>Human immunodeficiency virus (HIV)-1 is responsible for the dysregulation of the host immune system and the eventual development of acquired immunodeficiency syndrome (AIDS). Moreover, there are implications of HIV-induced chronic inflammation in the development of several comorbidities that have often been observed in HIV-infected populations, including cardiovascular atherosclerosis, kidney failure, diabetes, cancer, and HIV-associated neurocognitive disorders (HAND) (<xref ref-type="bibr" rid="ref6">Cassol et al., 2014</xref>; <xref ref-type="bibr" rid="ref46">Sailasuta et al., 2016</xref>; <xref ref-type="bibr" rid="ref24">Kaur et al., 2020</xref>). The neuropathogenesis of HIV infection begins with the virus particles entering the central nervous system (CNS) during early infection using infected monocytes and CD4+ T lymphocytes that cross the blood&#x2013;brain barrier (BBB) and subsequently have detrimental effects both directly due to viral replication and indirectly by dysregulating cellular metabolic processes (<xref ref-type="bibr" rid="ref18">Gonz&#x00E1;lez-Scarano and Mart&#x00ED;n-Garc&#x00ED;a, 2005</xref>; <xref ref-type="bibr" rid="ref50">Smith and Wilkins, 2015</xref>; <xref ref-type="bibr" rid="ref39">Pajkrt et al., 2016</xref>). In the CNS, these infected monocytes differentiate into macrophages, which, in turn, release viral particles that dysregulate all cell types within the CNS compartment as well as virions that infect perivascular macrophages and microglia (<xref ref-type="bibr" rid="ref18">Gonz&#x00E1;lez-Scarano and Mart&#x00ED;n-Garc&#x00ED;a, 2005</xref>; <xref ref-type="bibr" rid="ref50">Smith and Wilkins, 2015</xref>). In response, the HIV-infected brain macrophages, microglia, and multinucleated giant cells initiate astrocytosis (<xref ref-type="bibr" rid="ref46">Sailasuta et al., 2016</xref>). Moreover, HIV induces the activation of host cell metabolism to regulate the adaptive and innate immune responses of the host (<xref ref-type="bibr" rid="ref12">Deme et al., 2022</xref>). Collectively, these processes contribute to the development and clinical presentation of HAND. Symptoms of HAND may range in severity from asymptomatic neurocognitive impairment (ANI) to minor neurocognitive disorder (MND) and HIV-associated dementia (HAD) (<xref ref-type="bibr" rid="ref1">Antinori et al., 2007</xref>). HAND is associated with an increased risk for early mortality, independent of clinical predictors (<xref ref-type="bibr" rid="ref54">Vazquez-Santiago et al., 2014</xref>). While antiretroviral therapy (ART) has reduced the incidence of HIV-induced encephalopathy, 20&#x2013;50% of children and adults infected with HIV still develop HAND (<xref ref-type="bibr" rid="ref6">Cassol et al., 2014</xref>; <xref ref-type="bibr" rid="ref39">Pajkrt et al., 2016</xref>).</p>
<p>In the modern era of ART, there is a link between the aberrations in neuroimmunity and neurometabolic responses in people living with HIV and the development of HAND. In particular, positive feedback loops of immune-mediated tissue damage and repair mechanisms result in chronic inflammation, not entirely corrected with ART (<xref ref-type="bibr" rid="ref34">McArthur and Johnson, 2020</xref>). The excessive activation of various neuroimmune processes dysregulates normal neurometabolism in the host and results in cellular dysfunction and neurological damage (<xref ref-type="bibr" rid="ref18">Gonz&#x00E1;lez-Scarano and Mart&#x00ED;n-Garc&#x00ED;a, 2005</xref>; <xref ref-type="bibr" rid="ref39">Pajkrt et al., 2016</xref>). Interestingly, inflammation can be considered a better predictor for neurocognitive impairment than viral load or CD4+ T-cell counts (<xref ref-type="bibr" rid="ref39">Pajkrt et al., 2016</xref>). Perinatally infected children are more susceptible to the effects of HIV in the brain, most likely since the time of infection coincides with this critical period of brain development (<xref ref-type="bibr" rid="ref47">Schwartz and Major, 2006</xref>; <xref ref-type="bibr" rid="ref50">Smith and Wilkins, 2015</xref>; <xref ref-type="bibr" rid="ref39">Pajkrt et al., 2016</xref>; <xref ref-type="bibr" rid="ref56">Williams et al., 2021b</xref>). According to the 2022 UNAIDS report (<xref ref-type="bibr" rid="ref52">UNAIDS, 2022</xref>), there were approximately 1.7 million children under the age of 15&#x2009;years living with HIV. Perinatally infected children show neurodevelopmental delay and cognitive impairment, including visual, language, attention, memory, learning, and hearing disabilities (<xref ref-type="bibr" rid="ref50">Smith and Wilkins, 2015</xref>; <xref ref-type="bibr" rid="ref39">Pajkrt et al., 2016</xref>; <xref ref-type="bibr" rid="ref59">Yadav et al., 2017</xref>). Imaging studies indicate that the most common abnormalities in children infected with HIV are calcification of the basal ganglia and frontal periventricular white matter as well as altered cortical thickness and subcortical volumes that are likely due to neuronal and glial cell injury (<xref ref-type="bibr" rid="ref50">Smith and Wilkins, 2015</xref>; <xref ref-type="bibr" rid="ref59">Yadav et al., 2017</xref>; <xref ref-type="bibr" rid="ref34">McArthur and Johnson, 2020</xref>). This injury is likely due to the toxicity of viral proteins, dysregulation of cellular gene expression, and a pro-inflammatory skew, leading to high cerebrospinal fluid (CSF) levels of inflammatory mediators (<xref ref-type="bibr" rid="ref50">Smith and Wilkins, 2015</xref>; <xref ref-type="bibr" rid="ref39">Pajkrt et al., 2016</xref>; <xref ref-type="bibr" rid="ref59">Yadav et al., 2017</xref>; <xref ref-type="bibr" rid="ref34">McArthur and Johnson, 2020</xref>). There is a potential link between the sustained period of immune activation and neurocognitive damage in both adults and children (<xref ref-type="bibr" rid="ref50">Smith and Wilkins, 2015</xref>; <xref ref-type="bibr" rid="ref57">Williams et al., 2021a</xref>).</p>
<p>Considering all of the above, there is limited information regarding the mechanisms of pathogenesis of HIV in the CNS of perinatally infected children. Furthermore, most of the knowledge about potential neurometabolic abnormalities in children has been extrapolated from data collected from adults. The CSF directly interacts with the brain and provides unique insights into the CNS and its conditions. <xref ref-type="bibr" rid="ref56">Williams et al. (2021b)</xref> conducted a review that examined the association of inflammatory mediators with neurocognitive impairment in children with perinatal HIV infection and found only one study that used CSF samples. Metabolomics is a research approach that generates a more comprehensive characterization of the metabolites within biological samples. This method aims to identify and measure variations in metabolism, providing valuable insights into the changes to biological and cellular processes in response to a perturbation. Untargeted metabolomics is an impartial approach that involves minimal sample preparation, allowing for a comprehensive snapshot of a sample&#x2019;s metabolome, subsequently identifying disease markers, and providing a better understanding of underlying pathogenic mechanisms. This study aimed to employ proton nuclear magnetic resonance (<sup>1</sup>H-NMR) to generate an untargeted metabolomics dataset to investigate the metabolic underpinnings of HIV-induced neuropathogenesis in the CSF collected from a South African pediatric cohort. Furthermore, we offer new understanding and hypotheses for future investigations in this population.</p>
</sec>
<sec sec-type="methods|materials" id="sec6">
<label>2</label>
<title>Methods and materials</title>
<sec id="sec7">
<label>2.1</label>
<title>Sample collection</title>
<p>CSF samples were collected by lumbar puncture from 17 HIV+ and 50 HIV- pediatric patients &#x003C;12&#x2009;years old (average age [in months]&#x2009;&#x00B1;&#x2009;standard deviation: HIV+: 29.5&#x2009;&#x00B1;&#x2009;31.2, HIV&#x2212; 40&#x2009;&#x00B1;&#x2009;32.8) at Tygerberg Hospital in Cape Town, South Africa, in compliance with ethical practices and stored at &#x2212;80&#x00B0;C. All participants provided written informed consent and/or assent to use their CSF samples for research purposes. The study was approved by the Health Research Ethics Committee (HREC) of Stellenbosch University, Tygerberg Hospital (ethics approval no. N16/11/142), the Western Cape Provincial Government, and the HREC of the North-West University (NWU), Potchefstroom campus (ethics approval no. NWU-00063-18-A1). The frozen CSF samples were transported overnight to the Centre for Human Metabolomics at the Potchefstroom campus of the North-West University, where they were stored in a dedicated &#x2212;80&#x00B0;C freezer in a Biosafety Level 3 (BSL3) laboratory until analysis. All CSF samples were filtered by centrifugation through Amicon Ultra-2&#x2009;mL 10,000 MWCO centrifugal filters at 4,500&#x2009;&#x00D7;&#x2009;<italic>g</italic> for 20&#x2009;min to remove macromolecular components, such as proteins, and produce a sterile, non-infectious sample for further analysis. Hereafter, 100&#x2009;&#x03BC;L of the sample was aliquoted for <sup>1</sup>H-NMR analysis and an additional 20&#x2009;&#x03BC;L was aliquoted for use in a pooled quality control (QC) sample. <sup>1</sup>H-NMR was selected as the method of choice because it has a high throughput, utilizes a robust method that provides both quantitative and qualitative data on the metabolic composition of a sample, requires minimal sample preparation (does not chemically alter nor destroy the samples) that contributes toward high repeatability, and allows for the identification of metabolites with a high degree of confidence, with the aid of pure compound spectral libraries and two-dimensional <sup>1</sup>H-<sup>1</sup>H-NMR data.</p>
</sec>
<sec id="sec8">
<label>2.2</label>
<title>Chemicals</title>
<p>Potassium phosphate monobasic (KH<sub>2</sub>PO<sub>4</sub>), sodium azide (NaN<sub>3</sub>), and potassium hydroxide (KOH), were purchased from Sigma-Aldrich (St. Louis, Missouri, United States). Deuterium oxide and trimethylsilyl-2,2,3,3-tetradeuteropropionic acid (TSP) were acquired from Merck (Darmstadt, Germany).</p>
</sec>
<sec id="sec9">
<label>2.3</label>
<title>Sample preparation and <sup>1</sup>H-NMR analysis</title>
<p>An NMR buffer solution was prepared beforehand by dissolving potassium phosphate monobasic (KH<sub>2</sub>PO<sub>4</sub>) in deuterium oxide to a concentration of 1.5&#x2009;mM. Trimethylsilyl-2,2,3,3-tetradeuteropropionic acid (TSP) was added as a quantitative internal standard. Sodium azide (NaN<sub>3</sub>) dissolved in deuterium oxide was added to prevent bacterial growth. The pH of the solution was adjusted to 7.40 with potassium hydroxide. The standard operating procedure (SOP) used to prepare and analyze the CSF samples on the NMR is outlined in <xref ref-type="bibr" rid="ref53">van Zyl et al. (2020)</xref>, which briefly entails using 54&#x2009;&#x03BC;L of CSF and 6&#x2009;&#x03BC;L of NMR buffer in a 2-mm glass NMR tube. Samples were randomized and loaded onto a SampleXpress autosampler with the pooled QC samples placed intermittently, and the analysis was performed at 500&#x2009;MHz on a Bruker Avance III HD NMR Spectrometer.</p>
<p>Acquisition of <sup>1</sup>H spectra involved the collection of 128 transients, yielding 32&#x2009;K data points, utilizing a spectral width of 6,000&#x2009;Hz, and acquisition time of 2.72&#x2009;s. The receiver gain was adjusted to 64. The sample temperature was maintained at 300&#x2009;K, and the H<sub>2</sub>O resonance was suppressed through single-frequency irradiation (NOESY) during a relaxation delay of 4&#x2009;s, initiated by a 90&#x00B0; excitation pulse lasting 8&#x2009;&#x03BC;s. Automatic shimming was performed on the deuterium signal. Subsequently, Fourier transformation, phase correction, and baseline correction were carried out automatically. The quality of the spectra was verified by ensuring that the resonance line width for TSP was less than 1&#x2009;Hz. Bruker Topspin (v3.5) and Bruker AMIX (v3.4.19) were used for data processing, and binning and metabolite identification and quantification, respectively. Selective binning from 0.88&#x2009;ppm to 5.86&#x2009;ppm was done by selecting regions with discernible peaks and excluding regions of noise and exogenous compounds such as ethanol (used as a disinfectant during lumbar puncture) and glycerol (a component of the filter membranes) to create a data matrix of 117 bins, excluding the region of the water peak at ~4.7&#x2009;ppm.</p>
</sec>
<sec id="sec10">
<label>2.4</label>
<title>Statistical analysis</title>
<p>Group differences were assessed using the chi-square test. MetaboAnalyst (v5.0) (<ext-link xlink:href="https://scicrunch.org/resolver/RRID:SCR_015539" ext-link-type="uri">RRID:SCR_015539</ext-link>) was used for statistical data processing. Bins with QC relative standard deviation values higher than 25%, based on the median absolute deviation, were considered analytically unreliable, and removed. Hereafter, the data were normalized by applying log transformation and auto-scaling. Fold change (FC) analysis with a threshold of &#x003E; |1.5| was used to compare absolute value changes between the HIV+ and control groups. Principal component analysis (PCA) was performed to visualize the variance between the groups without taking the group classification into account. Partial least squares&#x2013;discriminant analysis (PLS-DA) was performed to identify the variables that best characterize the differentiated groups when taking group classification into account. PLS-DA variables of importance in projection (VIP) values greater than 1.0 were considered significant. The PLS-DA model was validated by performing a permutation test based on prediction accuracy. The significant bins selected by univariate and multivariate methods were used for metabolite identification by comparing their spectra with a purchased Bruker BioReference spectral library at pH 7.0 and in-house pure compound spectral libraries, after which these metabolites were quantified (&#x03BC;mol/L). IBM SPSS Statistics (v. 28.0.1.1) (<ext-link xlink:href="https://scicrunch.org/resolver/RRID:SCR_019096" ext-link-type="uri">RRID:SCR_019096</ext-link>) was used to perform the Mann&#x2013;Whitney <italic>U</italic>-test (a non-parametric <italic>t</italic>-test, selected due to the relatively small sample size and right-skewed distribution of the data) and determine Cohen&#x2019;s <italic>d</italic>-value for all these metabolites, with <italic>p</italic>&#x2009;&#x003C;&#x2009;0.05 and <italic>d</italic>&#x2009;&#x003E;&#x2009;|0.5| considered to be significant, respectively. Finally, Spearman&#x2019;s rho correlations were performed for the HIV+ group using IBM SPSS Statistics to identify significant correlations among the metabolites as well as significant correlations between metabolites and continuous clinical variables, while point-biserial correlation was performed for metabolites and dichotomous clinical variables. Correlations were considered significant at the 0.05 level (two-tailed), corrected for multiple comparisons using FDR.</p>
</sec>
</sec>
<sec sec-type="results" id="sec11">
<label>3</label>
<title>Results</title>
<sec id="sec12">
<label>3.1</label>
<title>Participants</title>
<p>CSF samples were obtained via lumbar puncture for routine diagnostic purposes between 2010 and 2017 from 67 pediatric patients under 12&#x2009;years of age who were suspected of having meningitis. Of these patients, 50 were HIV negative (controls), while 17 were HIV positive (HIV+). All patients underwent a comprehensive clinical evaluation, and their CSF was examined using various diagnostic techniques, including macroscopic appearance, total and differential cell count, protein, glucose, chloride, Gram stain, India ink examination, auramine &#x201C;O&#x201D; fluorescence microscopy, culture for pyogenic bacteria, culture for <italic>Mycobacterium tuberculosis</italic> (M.tb), GenoType MTBDRplus assay, and GeneXpert MTB/RIF<sup>&#x00AE;</sup> assay. HIV status was determined either by enzyme-linked immunosorbent assay (ELISA) or by HIV DNA polymerase chain reaction (PCR) tests. Of the 17 HIV+ children, 4 were on ART. Moreover, the HIV+ group presented with multiple co-infections, and six had concurrent extra-neural M.tb infection (non-CNS TB). M.tb-positive cases were excluded from the controls to obtain the healthiest possible control group to best characterize the metabolic profile of HIV. With regard to neurological symptoms, there were no significant differences between the HIV+ and control groups (<xref ref-type="table" rid="tab1">Table 1</xref>). For obvious ethical reasons, collecting CSF from healthy children is not a viable option, and this control group, although HIV and TB negative, did present to the clinic/hospital with other neurological complications. Consequently, the metabolites that were found to distinguish between the HIV+ and control groups could not have arisen due to a generic response to neurological injury or neuroinflammation. Thus, the features selected were specific to HIV infection. A summary of the pertinent clinical demographics of the cases used for metabolic profiling in this study is given in <xref ref-type="table" rid="tab1">Table 1</xref>.</p>
<table-wrap position="float" id="tab1">
<label>Table 1</label>
<caption>
<p>Clinical metadata.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th/>
<th align="center" valign="top">HIV+ (<italic>N</italic> =&#x2009;17)</th>
<th align="center" valign="top">Controls (<italic>N</italic> =&#x2009;50)</th>
<th align="center" valign="top">HIV vs. control</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Male/female, <italic>n</italic> (%)</td>
<td align="center" valign="top">12/5 (70.6/29.4)</td>
<td align="center" valign="top">34/16 (68/32)</td>
<td align="center" valign="top"><italic>p</italic> =&#x2009;1.000</td>
</tr>
<tr>
<td align="left" valign="top" colspan="4">
<bold>Age in months</bold>
</td>
</tr>
<tr>
<td align="left" valign="top">Average (SD)</td>
<td align="center" valign="top">29.5 (31.2)</td>
<td align="center" valign="top">40 (32.8)</td>
<td align="center" valign="top"><italic>p</italic> =&#x2009;0.240</td>
</tr>
<tr>
<td align="left" valign="top" colspan="4">
<bold>Clinical symptoms, <italic>n</italic> (%)</bold>
</td>
</tr>
<tr>
<td align="left" valign="top">Fever</td>
<td align="center" valign="top">13 (76.5)</td>
<td align="center" valign="top">31 (62)</td>
<td align="center" valign="top"><italic>p</italic> =&#x2009;0.408</td>
</tr>
<tr>
<td align="left" valign="top">Cough</td>
<td align="center" valign="top">11 (64.7)</td>
<td align="center" valign="top">14 (28)</td>
<td align="center" valign="top"><italic>p</italic> =&#x2009;0.005&#x002A;</td>
</tr>
<tr>
<td align="left" valign="top">Vomiting</td>
<td align="center" valign="top">6 (35.3)</td>
<td align="center" valign="top">26 (52)</td>
<td align="center" valign="top"><italic>p</italic> =&#x2009;0.333</td>
</tr>
<tr>
<td align="left" valign="top">Diarrhea</td>
<td align="center" valign="top">5 (29.4)</td>
<td align="center" valign="top">9 (18)</td>
<td align="center" valign="top"><italic>p</italic> =&#x2009;0.549</td>
</tr>
<tr>
<td align="left" valign="top">Weight loss</td>
<td align="center" valign="top">2 (11.8)</td>
<td align="center" valign="top">5 (10)</td>
<td align="center" valign="top"><italic>p</italic> =&#x2009;1.000</td>
</tr>
<tr>
<td align="left" valign="top">Headache</td>
<td align="center" valign="top">5 (29.4)</td>
<td align="center" valign="top">12 (24)</td>
<td align="center" valign="top"><italic>p</italic> =&#x2009;0.696</td>
</tr>
<tr>
<td align="left" valign="top">Decreased consciousness</td>
<td align="center" valign="top">2 (11.8)</td>
<td align="center" valign="top">10 (20)</td>
<td align="center" valign="top"><italic>p</italic> =&#x2009;0.235</td>
</tr>
<tr>
<td align="left" valign="top" colspan="4">
<bold>Concurrent infections, <italic>n</italic> (%)</bold>
</td>
</tr>
<tr>
<td align="left" valign="top">Pneumonia</td>
<td align="center" valign="top">5 (29.4)</td>
<td align="center" valign="top">9 (18)</td>
<td align="center" valign="top"><italic>p</italic> =&#x2009;0.242</td>
</tr>
<tr>
<td align="left" valign="top">Urinary tract infection</td>
<td align="center" valign="top">1 (5.8)</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top"><italic>p</italic> =&#x2009;0.418</td>
</tr>
<tr>
<td align="left" valign="top">Gastroenteritis</td>
<td align="center" valign="top">2 (11.8)</td>
<td align="center" valign="top">2 (4)</td>
<td align="center" valign="top"><italic>p</italic> =&#x2009;0.418</td>
</tr>
<tr>
<td align="left" valign="top">Varicella zoster infection</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">1 (2)</td>
<td align="center" valign="top"><italic>p</italic> =&#x2009;1.000</td>
</tr>
<tr>
<td align="left" valign="top">Flue</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">3 (6)</td>
<td align="center" valign="top"><italic>p</italic> =&#x2009;0.621</td>
</tr>
<tr>
<td align="left" valign="top">Tonsillitis</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">3 (6)</td>
<td align="center" valign="top"><italic>p</italic> =&#x2009;0.621</td>
</tr>
<tr>
<td align="left" valign="top">Abscesses</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">1 (2)</td>
<td align="center" valign="top"><italic>p</italic> =&#x2009;1.000</td>
</tr>
<tr>
<td align="left" valign="top"><italic>M.tb</italic> (non-CNS) infection</td>
<td align="center" valign="top">7 (41.2)</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top"><italic>p</italic> &#x2264;&#x2009;0.005&#x002A;</td>
</tr>
<tr>
<td align="left" valign="top" colspan="4">
<bold>Neurological symptoms</bold>
</td>
</tr>
<tr>
<td align="left" valign="top">Seizures</td>
<td align="center" valign="top">5 (29.4)</td>
<td align="center" valign="top">18 (36)</td>
<td align="center" valign="top"><italic>p</italic> =&#x2009;0.943</td>
</tr>
<tr>
<td align="left" valign="top">Raised intracranial pressure</td>
<td align="center" valign="top">1 (5.8)</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top"><italic>p</italic> =&#x2009;0.622</td>
</tr>
<tr>
<td align="left" valign="top">Meningeal irritation</td>
<td align="center" valign="top">3 (17.5)</td>
<td align="center" valign="top">5 (10)</td>
<td align="center" valign="top"><italic>p</italic> =&#x2009;0.311</td>
</tr>
<tr>
<td align="left" valign="top">Brainstem dysfunction</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">1 (2)</td>
<td align="center" valign="top"><italic>p</italic> =&#x2009;1.000</td>
</tr>
<tr>
<td align="left" valign="top">Infarction</td>
<td align="center" valign="top">2 (11.8)</td>
<td align="center" valign="top">1 (2)</td>
<td align="center" valign="top"><italic>p</italic> =&#x2009;0.351</td>
</tr>
<tr>
<td align="left" valign="top">Basal enhancement</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">3 (7)</td>
<td align="center" valign="top"><italic>p</italic> =&#x2009;0.684</td>
</tr>
<tr>
<td align="left" valign="top">Hydrocephalus</td>
<td align="center" valign="top">1 (5.8)</td>
<td align="center" valign="top">1 (2)</td>
<td align="center" valign="top"><italic>p</italic> =&#x2009;1.000</td>
</tr>
<tr>
<td align="left" valign="top">Hemiplegia</td>
<td align="center" valign="top">2 (11.8)</td>
<td align="center" valign="top">1 (2)</td>
<td align="center" valign="top"><italic>p</italic> =&#x2009;0.071</td>
</tr>
<tr>
<td align="left" valign="top">Abnormal MRI</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">0</td>
<td/>
</tr>
<tr>
<td align="left" valign="top" colspan="4">
<bold>CSF cell count (cells per &#x03BC;L CSF)</bold>
</td>
</tr>
<tr>
<td align="left" valign="top">Erythrocytes [median (IQR)]</td>
<td align="center" valign="top">0 (0&#x2013;115.5)</td>
<td align="center" valign="top">0 (0&#x2013;1)</td>
<td align="center" valign="top"><italic>p</italic> =&#x2009;0.394</td>
</tr>
<tr>
<td align="left" valign="top">Leukocytes [median (IQR)]</td>
<td align="center" valign="top">1 (0&#x2013;2)</td>
<td align="center" valign="top">0 (0&#x2013;1)</td>
<td align="center" valign="top"><italic>p</italic> =&#x2009;0.947</td>
</tr>
<tr>
<td align="left" valign="top">PMNs [median (IQR)]</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top"><italic>p</italic> =&#x2009;0.890</td>
</tr>
<tr>
<td align="left" valign="top">Lymphocytes [median (IQR)]</td>
<td align="center" valign="top">1 (0&#x2013;1.5)</td>
<td align="center" valign="top">0 (0&#x2013;1)</td>
<td align="center" valign="top"><italic>p</italic> =&#x2009;0.975</td>
</tr>
<tr>
<td align="left" valign="top">CSF protein (g/L) [median (IQR)]</td>
<td align="center" valign="top">0.2 (0.2&#x2013;0.3)</td>
<td align="center" valign="top">0.17 (0.14&#x2013;0.27)</td>
<td align="center" valign="top"><italic>p</italic> =&#x2009;0.430</td>
</tr>
<tr>
<td align="left" valign="top">CSF glucose (mmol/L) [median (IQR)]</td>
<td align="center" valign="top">3.3 (3.2&#x2013;4)</td>
<td align="center" valign="top">3.8 (3.4&#x2013;4.1)</td>
<td align="center" valign="top"><italic>p</italic> =&#x2009;0.352</td>
</tr>
<tr>
<td align="left" valign="top">CD4 count (cells/&#x03BC;L) [median (IQR)]</td>
<td align="center" valign="top">142.5 (10.7&#x2013;383.8)</td>
<td align="center" valign="top">N/A</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">CD4 count (%) [median (IQR)]</td>
<td align="center" valign="top">22 (19.5&#x2013;27)</td>
<td align="center" valign="top">N/A</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">Viral load (copies/mL) [median (IQR)]</td>
<td align="center" valign="top">250,000 (199,750&#x2013;250,000)</td>
<td align="center" valign="top">N/A</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">On AART, <italic>n</italic> (%)</td>
<td align="center" valign="top">4 (23.5)</td>
<td align="center" valign="top">0</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">Details of AART</td>
<td align="center" valign="top">Kaletra, stavudine, 3TC&#x2014;duration 4&#x2009;months</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td align="center" valign="top">Kaletra, abacavir, ritonavir, 3TC&#x2014;duration 25&#x2009;days</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td align="center" valign="top">Abacavir, kaletra, 3TC&#x2014;duration 10&#x2009;months</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td align="center" valign="top">Lamivudine, abacavir, lopinavir/ritonavir&#x2014;duration 21&#x2009;days</td>
<td/>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>Group differences were assessed using the chi-squared test with <italic>p</italic>&#x2009;&#x003C;&#x2009;0.05 considered significant.N, number; SD, standard deviation; IQR, interquartile range; M.tb, <italic>Mycobacterium tuberculosis</italic>; CNS, central nervous system; CSF, cerebrospinal fluid.</p>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec13">
<label>3.2</label>
<title>Significant bins identified by multivariate and univariate methods</title>
<sec id="sec14">
<label>3.2.1</label>
<title>Principal component analysis</title>
<p><xref ref-type="fig" rid="fig1">Figure 1A</xref> shows the clustering of the QC and the experimental samples. The scores plot shows that the QC samples cluster closely together, showing far less variation than the patient samples, indicating the precision of the analysis and data collection. Seven control samples appeared outside the PCA 95% confidence interval and were removed as outliers (<xref ref-type="bibr" rid="ref44">Puchades-Carrasco et al., 2016</xref>). Thus, 43 control samples were compared to 17 HIV+ samples for this analysis. A visual inspection of the PCA scores plot shows a partial separation between PC1 vs. PC4 (<xref ref-type="fig" rid="fig1">Figure 1B</xref>) between the HIV+ and control groups, comparatively.</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p><bold>(A)</bold> PCA scores plot of PC 1 and 2 indicating grouping of QC samples (blue) vs. the 17 HIV+ (green) and 43 control (red) samples. The tighter clustering of the QC samples indicates the repeatability of the analysis. <bold>(B)</bold> PCA scores plot of PC 1 and 4 indicating a partial separation between the 17 HIV+ (green) and 43 control (red) samples. <bold>(C)</bold> PLS-DA scores plot indicating grouping between the 17 HIV+ (green) and 43 control (red) samples.</p>
</caption>
<graphic xlink:href="fnins-18-1270041-g001.tif"/>
</fig>
</sec>
<sec id="sec15">
<label>3.2.2</label>
<title>Partial least squares&#x2013;discriminant analysis</title>
<p>A PLS-DA modeling (<xref ref-type="fig" rid="fig1">Figure 1C</xref>) was performed to identify spectral bins that differentiated between the HIV+ and control groups. The PLS-DA model was validated (<italic>p</italic>&#x2009;=&#x2009;0.0005) by performing a permutation test (<italic>n</italic>&#x2009;=&#x2009;2,000) based on prediction accuracy, and provided a reasonable measure for the Q2 value, indicating that the PLS-DA model does not suffer from overfitting and the class separation results are based upon predictions, instead of fitted results (<xref ref-type="bibr" rid="ref55">Westerhuis et al., 2008</xref>). The bins (VIP&#x2009;&#x003E;&#x2009;1.0) identified by PLS-DA that are significantly increased in the HIV+ group comparatively include 4.09, 3.61, 4.07, 1.13, 1.35, 3.31, 4.11, 2.07, 1.33, 3.53, 3.29, 2.49, and 4.13. Bins that are significantly decreased in the HIV+ group comparatively are 3.35, 3.25, 3.49, 3.41, 2.39, 3.51, 5.25, 3.39, 3.23, 2.29, 3.43, 3.83, and 0.91.</p>
</sec>
<sec id="sec16">
<label>3.2.3</label>
<title>Univariate analysis</title>
<p>The significant bins (summarized in <xref ref-type="table" rid="tab2">Table 2</xref>), selected by absolute fold change (FC)&#x2009;&#x003E;&#x2009;|1.5|, which are increased in the HIV+ group compared to the control group, are: 4.09, 3.61, 4.07, 1.13, 3.31, and 3.29, while 2.29 was decreased comparatively. There are, however, no statistically significant bins (<italic>p</italic>&#x2009;&#x003C;&#x2009;0.1) based on the Wilcoxon test.</p>
<table-wrap position="float" id="tab2">
<label>Table 2</label>
<caption>
<p>Summary of statistical findings for binned dataset.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Bins</th>
<th align="center" valign="top">VIP</th>
<th>FC</th>
<th>Log2(FC)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">4.09</td>
<td align="char" valign="top" char=".">2.12</td>
<td align="char" valign="top" char=".">1.72</td>
<td align="char" valign="top" char=".">0.78</td>
</tr>
<tr>
<td align="left" valign="top">3.61</td>
<td align="char" valign="top" char=".">1.83</td>
<td align="char" valign="top" char=".">1.85</td>
<td align="char" valign="top" char=".">0.88</td>
</tr>
<tr>
<td align="left" valign="top">4.07</td>
<td align="char" valign="top" char=".">1.78</td>
<td align="char" valign="top" char=".">1.97</td>
<td align="char" valign="top" char=".">0.98</td>
</tr>
<tr>
<td align="left" valign="top">1.13</td>
<td align="char" valign="top" char=".">1.43</td>
<td align="char" valign="top" char=".">3.03</td>
<td align="char" valign="top" char=".">1.60</td>
</tr>
<tr>
<td align="left" valign="top">1.35</td>
<td align="char" valign="top" char=".">1.54</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">3.35</td>
<td align="char" valign="top" char=".">1.31</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">3.25</td>
<td align="char" valign="top" char=".">1.36</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">3.49</td>
<td align="char" valign="top" char=".">1.32</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">3.31</td>
<td align="char" valign="top" char=".">1.27</td>
<td align="char" valign="top" char=".">1.84</td>
<td align="char" valign="top" char=".">0.88</td>
</tr>
<tr>
<td align="left" valign="top">3.41</td>
<td align="char" valign="top" char=".">1.28</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">4.11</td>
<td align="char" valign="top" char=".">1.34</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">2.07</td>
<td align="char" valign="top" char=".">1.14</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">2.39</td>
<td align="char" valign="top" char=".">1.21</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">1.33</td>
<td align="char" valign="top" char=".">1.35</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">3.51</td>
<td align="char" valign="top" char=".">1.19</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">5.25</td>
<td align="char" valign="top" char=".">1.19</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">3.39</td>
<td align="char" valign="top" char=".">1.16</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">3.53</td>
<td align="char" valign="top" char=".">1.15</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">3.23</td>
<td align="char" valign="top" char=".">1.15</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">3.29</td>
<td align="char" valign="top" char=".">1.14</td>
<td align="char" valign="top" char=".">1.77</td>
<td align="char" valign="top" char=".">0.82</td>
</tr>
<tr>
<td align="left" valign="top">2.29</td>
<td align="char" valign="top" char=".">1.08</td>
<td align="char" valign="top" char=".">0.36</td>
<td align="char" valign="top" char=".">&#x2212;1.47</td>
</tr>
<tr>
<td align="left" valign="top">2.49</td>
<td align="char" valign="top" char=".">1.02</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">3.43</td>
<td align="char" valign="top" char=".">1.09</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">3.83</td>
<td align="char" valign="top" char=".">1.06</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">0.91</td>
<td align="char" valign="top" char=".">1.04</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">4.13</td>
<td align="char" valign="top" char=".">1.12</td>
<td/>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>The variables of importance in projection (VIP) were selected by PLS-DA with a threshold of &#x003E;1.0. Bins found to have a fold change (FC)&#x2009;&#x003E;&#x2009;|1.5| were considered significant.</p>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec17">
<label>3.2.4</label>
<title>Quantified metabolites</title>
<p>The metabolite identities of significant bins were confirmed using the two-dimensional (<sup>1</sup>H-<sup>1</sup>H JRES and COSY) NMR spectral data, and comparison to the pure compound spectral libraries, followed by absolute quantification (&#x03BC;mol/L). Metabolites that are significantly increased, based on PLS-DA VIP&#x2009;&#x003E;&#x2009;1.0, in the HIV+ group compared to the controls are lactate (bins 4.09, 1.35, 4.11, 1.33, 4.13), myo-inositol (bins 3.61, 3.31, 3.53, 3.29), 1,2-propanediol (bins 4.07, 1.13), and glutamine (bin 2.49). The significantly decreased metabolites, based upon PLS-DA VIP&#x2009;&#x003E;&#x2009;1.0, in the HIV+ group comparatively, are glucose (bins 3.25, 3.49, 3.41, 3.51, 5.25, 3.39, 3.23, 3.43, 3.83), 3-hydroxybutyrate (bin 2.39), acetoacetate (bin 2.29), and 2-hydroxybutyrate (bin 0.91). Identification and quantification of the significant bins, also selected by fold change, revealed that the metabolites that are increased in the HIV+ group compared to the controls are 1,2-propanediol (bins 4.07, 1.13), myo-inositol (bins 3.61, 3.31, 3.29), and lactate (bin 4.09), while acetoacetate (bins 2.29) is decreased.</p>
<p>The quantified metabolic data and metabolite ratios are presented visually as box plots (<xref ref-type="fig" rid="fig2">Figure 2</xref>) and quantitatively in <xref ref-type="table" rid="tab3">Table 3</xref>. It is important to note that acetoacetate and 3-hydroxybutyrate occupied the same significant <sup>1</sup>H-NMR spectral bin; however, upon concentration quantification, it was found that acetoacetate did not significantly differ between the two groups. As an additional evaluation of the potential importance of ketone bodies, the metabolite concentration of acetone was also calculated. Calculation of the Mann&#x2013;Whitney <italic>U</italic>-test with <italic>p</italic>&#x2009;&#x003C;&#x2009;0.05 indicates that metabolites that are significantly increased in the HIV+ group comparatively include myo-inositol and 1,2-propanediol, while 3-hydroxybutyrate is decreased in the HIV+ group comparatively. Cohen&#x2019;s <italic>d</italic> value is a measure of effect size, indicating the strength of the relationship between two variables in a population. Cohen&#x2019;s <italic>d</italic>-value calculation indicates that the metabolites: Lactate, 1,2-propanediol, 3-hydroxybutyrate, acetone, and myo-inositol have significant effect sizes (<italic>d</italic>&#x2009;&#x003E;&#x2009;|0.5|).</p>
<fig position="float" id="fig2">
<label>Figure 2</label>
<caption>
<p>Boxplots for concentrations (&#x03BC;mol/L) of CSF metabolites characterizing HIV&#x2014;glucose, lactate&#x002A;, 2-hydroxybutyrate, acetone&#x002A;, 3-hydroxybutyrate&#x002A;, acetoacetate, myo-inositol&#x002A;, glutamine, and 1,2-propanediol&#x002A; as well as metabolite ratios: lactate/glucose&#x002A;, lactate/pyruvate, and 3-hyrdorxybutyrate/acetoacetate&#x002A;. &#x002A; Indicates the metabolites and ratios that had significant effect sizes (<italic>d</italic>&#x2009;&#x003E;&#x2009;0.5) when comparing the 17 HIV+ (green) and 43 control (red) samples.</p>
</caption>
<graphic xlink:href="fnins-18-1270041-g002.tif"/>
</fig>
<table-wrap position="float" id="tab3">
<label>Table 3</label>
<caption>
<p>Summary of statistical findings for quantified metabolites.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top" rowspan="2">Metabolite</th>
<th align="center" valign="top" colspan="3">HIV</th>
<th align="center" valign="top" colspan="3">Controls</th>
<th align="center" valign="top" colspan="2">HIV vs. controls</th>
</tr>
<tr>
<th align="center" valign="top">Average conc. (&#x03BC;mol/L)</th>
<th align="center" valign="top">&#x00B1;</th>
<th align="center" valign="top">Standard deviation</th>
<th align="center" valign="top">Average conc. (&#x03BC;mol/L)</th>
<th align="center" valign="top">&#x00B1;</th>
<th align="center" valign="top">Standard deviation</th>
<th align="center" valign="top"><italic>p</italic>-value</th>
<th align="center" valign="top"><italic>d</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Glucose</td>
<td align="center" valign="top">2818.01</td>
<td align="center" valign="top">&#x00B1;</td>
<td align="center" valign="top">690.94</td>
<td align="center" valign="top">3024.34</td>
<td align="center" valign="top">&#x00B1;</td>
<td align="center" valign="top">552.30</td>
<td align="center" valign="top">0.288</td>
<td align="center" valign="top">&#x2212;0.352</td>
</tr>
<tr>
<td align="left" valign="top">Pyruvate</td>
<td align="center" valign="top">51.62</td>
<td align="center" valign="top">&#x00B1;</td>
<td align="center" valign="top">36.24</td>
<td align="center" valign="top">45.58</td>
<td align="center" valign="top">&#x00B1;</td>
<td align="center" valign="top">25.21</td>
<td align="center" valign="top">0.508</td>
<td align="center" valign="top">0.322</td>
</tr>
<tr>
<td align="left" valign="top">Lactate</td>
<td align="center" valign="top">2285.20</td>
<td align="center" valign="top">&#x00B1;</td>
<td align="center" valign="top">912.51</td>
<td align="center" valign="top">1923.85</td>
<td align="center" valign="top">&#x00B1;</td>
<td align="center" valign="top">469.05</td>
<td align="center" valign="top">0.246</td>
<td align="center" valign="top">
<bold>0.521&#x002A;</bold>
</td>
</tr>
<tr>
<td align="left" valign="top">Lactate:pyruvate ratio</td>
<td align="center" valign="top">53.71</td>
<td align="center" valign="top">&#x00B1;</td>
<td align="center" valign="top">25.44</td>
<td align="center" valign="top">54.26</td>
<td align="center" valign="top">&#x00B1;</td>
<td align="center" valign="top">26.81</td>
<td align="center" valign="top">0.889</td>
<td align="center" valign="top">0.002</td>
</tr>
<tr>
<td align="left" valign="top">Lactate:glucose ratio</td>
<td align="center" valign="top">0.81</td>
<td align="center" valign="top">&#x00B1;</td>
<td align="center" valign="top">0.23</td>
<td align="center" valign="top">0.64</td>
<td align="center" valign="top">&#x00B1;</td>
<td align="center" valign="top">0.13</td>
<td align="center" valign="top">
<bold>0.008&#x002A;</bold>
</td>
<td align="center" valign="top">
<bold>0.791&#x002A;</bold>
</td>
</tr>
<tr>
<td align="left" valign="top">Glutamine</td>
<td align="center" valign="top">618.46</td>
<td align="center" valign="top">&#x00B1;</td>
<td align="center" valign="top">209.38</td>
<td align="center" valign="top">561.69</td>
<td align="center" valign="top">&#x00B1;</td>
<td align="center" valign="top">141.43</td>
<td align="center" valign="top">0.541</td>
<td align="center" valign="top">0.231</td>
</tr>
<tr>
<td align="left" valign="top">1,2-Propanediol</td>
<td align="center" valign="top">985.70</td>
<td align="center" valign="top">&#x00B1;</td>
<td align="center" valign="top">1433.04</td>
<td align="center" valign="top">303.95</td>
<td align="center" valign="top">&#x00B1;</td>
<td align="center" valign="top">377.23</td>
<td align="center" valign="top">
<bold>0.007&#x002A;</bold>
</td>
<td align="center" valign="top">
<bold>0.850&#x002A;</bold>
</td>
</tr>
<tr>
<td align="left" valign="top">Acetone</td>
<td align="center" valign="top">15.06</td>
<td align="center" valign="top">&#x00B1;</td>
<td align="center" valign="top">8.40</td>
<td align="center" valign="top">37.46</td>
<td align="center" valign="top">&#x00B1;</td>
<td align="center" valign="top">43.30</td>
<td align="center" valign="top">0.322</td>
<td align="center" valign="top">
<bold>&#x2212;0.590&#x002A;</bold>
</td>
</tr>
<tr>
<td align="left" valign="top">3-Hydroxybutyrate</td>
<td align="center" valign="top">30.49</td>
<td align="center" valign="top">&#x00B1;</td>
<td align="center" valign="top">32.44</td>
<td align="center" valign="top">93.61</td>
<td align="center" valign="top">&#x00B1;</td>
<td align="center" valign="top">117.75</td>
<td align="center" valign="top">
<bold>0.017&#x002A;</bold>
</td>
<td align="center" valign="top">
<bold>&#x2212;0.594&#x002A;</bold>
</td>
</tr>
<tr>
<td align="left" valign="top">Acetoacetate</td>
<td align="center" valign="top">51.92</td>
<td align="center" valign="top">&#x00B1;</td>
<td align="center" valign="top">37.32</td>
<td align="center" valign="top">46.23</td>
<td align="center" valign="top">&#x00B1;</td>
<td align="center" valign="top">24.18</td>
<td align="center" valign="top">0.961</td>
<td align="center" valign="top">0.193</td>
</tr>
<tr>
<td align="left" valign="top">3-Hydroxybutyrate: acetoacetate ratio</td>
<td align="center" valign="top">0.73</td>
<td align="center" valign="top">&#x00B1;</td>
<td align="center" valign="top">0.60</td>
<td align="center" valign="top">2.20</td>
<td align="center" valign="top">&#x00B1;</td>
<td align="center" valign="top">2.58</td>
<td align="center" valign="top">
<bold>0.030&#x002A;</bold>
</td>
<td align="center" valign="top">
<bold>&#x2212;0.633&#x002A;</bold>
</td>
</tr>
<tr>
<td align="left" valign="top">2-Hydroxybutyrate</td>
<td align="center" valign="top">43.48</td>
<td align="center" valign="top">&#x00B1;</td>
<td align="center" valign="top">35.06</td>
<td align="center" valign="top">43.35</td>
<td align="center" valign="top">&#x00B1;</td>
<td align="center" valign="top">19.92</td>
<td align="center" valign="top">0.305</td>
<td align="center" valign="top">0.013</td>
</tr>
<tr>
<td align="left" valign="top">Myo-inositol</td>
<td align="center" valign="top">590.64</td>
<td align="center" valign="top">&#x00B1;</td>
<td align="center" valign="top">509.20</td>
<td align="center" valign="top">244.82</td>
<td align="center" valign="top">&#x00B1;</td>
<td align="center" valign="top">107.37</td>
<td align="center" valign="top">
<bold>0.049&#x002A;</bold>
</td>
<td align="center" valign="top">
<bold>1.182&#x002A;</bold>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>The Mann&#x2013;Whitney <italic>U</italic>-test was used to obtain <italic>p</italic>-values with <italic>p</italic>&#x2009;&#x003C;&#x2009;0.05 considered significant. Effect sizes are considered significant at <italic>d</italic>&#x2009;&#x003E;&#x2009;0.5. Conc., concentration.</p>
</table-wrap-foot>
</table-wrap>
<p>In addition, the lactate:pyruvate ratio and 3-hydroxybutyrate:acetoacetate ratio were determined to assess redox status, at the cytoplasm and mitochondrial levels, respectively. The lactate:glucose ratio was also calculated to indicate flux through glycolysis, into lactate.</p>
</sec>
<sec id="sec18">
<label>3.2.5</label>
<title>Correlations among metabolites</title>
<p>Spearman&#x2019;s rho correlations indicate significant associations among several of the VIP metabolites. The correlation results are given in the supplementary information section. Glucose significantly positively correlates with the metabolites lactate (<italic>r</italic> =&#x2009;0.524; <italic>p</italic>&#x2009;=&#x2009;0.035), 3-hydroxybutyrate (<italic>r</italic>&#x2009;=&#x2009;0.539; <italic>p</italic>&#x2009;=&#x2009;0.035), acetoacetate (<italic>r</italic>&#x2009;=&#x2009;0.507; <italic>p</italic>&#x2009;=&#x2009;0.040), and 2-hydroxybutyrate (<italic>r</italic>&#x2009;=&#x2009;0.667; <italic>p</italic>&#x2009;=&#x2009;0.012). Lactate also significantly positively correlates with the metabolites: acetone (<italic>r</italic>&#x2009;=&#x2009;0.576; <italic>p</italic>&#x2009;=&#x2009;0.031), acetoacetate (<italic>r</italic>&#x2009;=&#x2009;0.701; <italic>p</italic>&#x2009;=&#x2009;0.011), and 2-hydroxybutyrate (<italic>r</italic>&#x2009;=&#x2009;0.652; <italic>p</italic>&#x2009;=&#x2009;0.013). The 1,2-propanediol significantly positively correlates with acetone (<italic>r</italic>&#x2009;=&#x2009;0.569; <italic>p</italic>&#x2009;=&#x2009;0.039). 3-Hydroxybutyrate significantly positively correlates with acetone (<italic>r</italic>&#x2009;=&#x2009;0.588; <italic>p</italic>&#x2009;=&#x2009;0.031), glutamine (<italic>r</italic>&#x2009;=&#x2009;0.713; <italic>p</italic>&#x2009;=&#x2009;0.011), and 2-hydroxybutyrate (<italic>r</italic>&#x2009;=&#x2009;0.586; <italic>p</italic>&#x2009;=&#x2009;0.027). The 2-hydroxybutyrate significantly positively correlates with acetone (<italic>r</italic>&#x2009;=&#x2009;0.691, <italic>p</italic>&#x2009;=&#x2009;0.012). Glutamine significantly positively correlates with acetone (<italic>r</italic>&#x2009;=&#x2009;0.800; <italic>p</italic>&#x2009;=&#x2009;0.010) and 2-hydroxybutyrate (<italic>r</italic>&#x2009;=&#x2009;0.696; <italic>p</italic>&#x2009;=&#x2009;0.011). Myo-inositol significantly positively correlates with glutamine (<italic>r</italic>&#x2009;=&#x2009;0.653; <italic>p</italic>&#x2009;=&#x2009;0.016).</p>
</sec>
<sec id="sec19">
<label>3.2.6</label>
<title>Correlations of metabolites with clinical features</title>
<p>Several significant associations were found between the VIP metabolites and clinical variables. Glucose significantly positively correlated with fever (<italic>r</italic>&#x2009;=&#x2009;0.656; <italic>p</italic>&#x2009;=&#x2009;0.014). Lactic acid significantly positively correlated with right hemiplegia (<italic>r</italic>&#x2009;=&#x2009;0.704; <italic>p</italic>&#x2009;=&#x2009;0.021) and CSF lymphocyte count (<italic>r</italic>&#x2009;=&#x2009;0.661, <italic>p</italic>&#x2009;=&#x2009;0.036). Myo-inositol significantly positively correlated with CSF protein (<italic>r</italic>&#x2009;=&#x2009;0.629; <italic>p</italic>&#x2009;=&#x2009;0.040), meningeal irritation (<italic>r</italic>&#x2009;=&#x2009;0.678; <italic>p</italic>&#x2009;=&#x2009;0.034), and cough (<italic>r</italic>&#x2009;=&#x2009;0.583; <italic>p</italic>&#x2009;=&#x2009;0.034). 1,2-Propanediol significantly negatively correlates with age (<italic>r</italic>&#x2009;=&#x2009;&#x2212;0.526; <italic>p</italic>&#x2009;=&#x2009;0.043). 3-Hydroxybutyric acid significantly correlated with viral count (<italic>r</italic>&#x2009;=&#x2009;0.784; <italic>p</italic>&#x2009;=&#x2009;0.032), left hemiplegia (<italic>r</italic>&#x2009;=&#x2009;&#x2212;0.680; <italic>p</italic>&#x2009;=&#x2009;0.029), decreased consciousness (<italic>r</italic>&#x2009;=&#x2009;&#x2212;0.627; <italic>p</italic>&#x2009;=&#x2009;0.021), and fever (<italic>r</italic>&#x2009;=&#x2009;&#x2212;0.627; <italic>p</italic>&#x2009;=&#x2009;0.047). Acetoacetate was significantly negatively correlated with a urinary tract infection (<italic>r</italic>&#x2009;=&#x2009;&#x2212;0.631; <italic>p</italic>&#x2009;=&#x2009;0.017). Glutamine significantly correlated with viral count (<italic>r</italic>&#x2009;=&#x2009;0.825; <italic>p</italic>&#x2009;=&#x2009;0.026), meningeal irritation (<italic>r</italic>&#x2009;=&#x2009;0.648; <italic>p</italic>&#x2009;=&#x2009;0.044), infarctions (<italic>r</italic>&#x2009;=&#x2009;&#x2212;0.584; <italic>p</italic>&#x2009;=&#x2009;0.034), and vomiting (<italic>r</italic>&#x2009;=&#x2009;0.519; <italic>p</italic>&#x2009;=&#x2009;0.045). 2-Hydroxybutyric acid significantly correlated with CSF protein (<italic>r</italic>&#x2009;=&#x2009;0.738; <italic>p</italic>&#x2009;=&#x2009;0.021), meningeal irritation (<italic>r</italic>&#x2009;=&#x2009;0.608; <italic>p</italic>&#x2009;=&#x2009;0.048), right hemiplegia (<italic>r</italic>&#x2009;=&#x2009;0.657; <italic>p</italic>&#x2009;=&#x2009;0.034), left hemiplegia (<italic>r</italic>&#x2009;=&#x2009;&#x2212;0.606; <italic>p</italic>&#x2009;=&#x2009;0.045), deceased (<italic>r</italic>&#x2009;=&#x2009;0.492; <italic>p</italic>&#x2009;=&#x2009;0.047), and fever (<italic>r</italic>&#x2009;=&#x2009;0.601; <italic>p</italic>&#x2009;=&#x2009;0.021).</p>
</sec>
<sec id="sec20">
<label>3.2.7</label>
<title>Correlations among clinical features</title>
<p>Several significant associations were found among the clinical variables. CD4 count positively correlated with ART exposure (<italic>r</italic>&#x2009;=&#x2009;0.762; <italic>p</italic>&#x2009;=&#x2009;0.030), infarctions (<italic>r</italic>&#x2009;=&#x2009;0.633; <italic>p</italic>&#x2009;=&#x2009;0.049), left hemiplegia (<italic>r</italic>&#x2009;=&#x2009;0.866; <italic>p</italic>&#x2009;=&#x2009;0.015), and gastroenteritis (<italic>r</italic>&#x2009;=&#x2009;0.612; <italic>p</italic>&#x2009;=&#x2009;0.045). Age significantly correlated with seizures (<italic>r</italic>&#x2009;=&#x2009;0.631; <italic>p</italic>&#x2009;=&#x2009;0.021) and TB contact (<italic>r</italic>&#x2009;=&#x2009;0.669; <italic>p</italic>&#x2009;=&#x2009;0.014). Raised intracranial pressure significantly correlated with hydrocephalus (<italic>r</italic>&#x2009;=&#x2009;1.000; <italic>p</italic>&#x2009;=&#x2009;0.001). Hydrocephalus significantly negatively correlated with fever (<italic>r</italic>&#x2009;=&#x2009;&#x2212;0.535; <italic>p</italic>&#x2009;=&#x2009;0.045). Meningeal irritation significantly correlated with vomiting (<italic>r</italic>&#x2009;=&#x2009;0.671; <italic>p</italic>&#x2009;=&#x2009;0.035) and TB contact (<italic>r</italic>&#x2009;=&#x2009;0.810; <italic>p</italic>&#x2009;=&#x2009;0.009). Infarctions significantly correlated with left hemiplegia (<italic>r</italic>&#x2009;=&#x2009;0.674; <italic>p</italic>&#x2009;=&#x2009;0.030) and decreased consciousness (<italic>r</italic>&#x2009;=&#x2009;0.679; <italic>p</italic>&#x2009;=&#x2009;0.019). Right hemiplegia significantly correlated with deceased status (<italic>r</italic>&#x2009;=&#x2009;1.000; <italic>p</italic>&#x2009;=&#x2009;0.001) and gastroenteritis (<italic>r</italic>&#x2009;=&#x2009;1.000; <italic>p</italic>&#x2009;=&#x2009;0.001). Gastroenteritis also significantly correlated with deceased status (<italic>r</italic> =&#x2009;0.685; <italic>p</italic>&#x2009;=&#x2009;0.009). Left hemiplegia significantly correlated with decreased consciousness (<italic>r</italic>&#x2009;=&#x2009;1.000; <italic>p</italic>&#x2009;=&#x2009;0.001) and fever (<italic>r</italic>&#x2009;=&#x2009;&#x2212;0.674; <italic>p</italic>&#x2009;=&#x2009;0.030). Diarrhea significantly correlated with gastroenteritis (<italic>r</italic>&#x2009;=&#x2009;0.561; <italic>p</italic>&#x2009;=&#x2009;0.009). Seizures significantly correlated with TB contact (<italic>r</italic>&#x2009;=&#x2009;0.707; <italic>p</italic>&#x2009;=&#x2009;0.011), cough (<italic>r</italic>&#x2009;=&#x2009;&#x2212;0.709; <italic>p</italic>&#x2009;=&#x2009;0.009), and pneumonia (<italic>r</italic>&#x2009;=&#x2009;&#x2212;0.522; <italic>p</italic>&#x2009;=&#x2009;0.045). Cough significantly correlated with TB co-infection (<italic>r</italic>&#x2009;=&#x2009;0.522; <italic>p</italic>&#x2009;=&#x2009;0.045) and pneumonia (<italic>r</italic>&#x2009;=&#x2009;0.522; <italic>p</italic>&#x2009;=&#x2009;0.045). Erythrocyte count significantly correlated with a urinary tract infection (<italic>r</italic>&#x2009;=&#x2009;0.899; <italic>p</italic>&#x2009;=&#x2009;0.001). Gastroenteritis significantly correlated with leukocyte count (<italic>r</italic>&#x2009;=&#x2009;0.911; <italic>p</italic>&#x2009;=&#x2009;0.001), lymphocyte count (<italic>r</italic>&#x2009;=&#x2009;0.925; <italic>p</italic>&#x2009;=&#x2009;0.001), CSF protein levels (<italic>r</italic>&#x2009;=&#x2009;0.631; <italic>p</italic>&#x2009;=&#x2009;0.045), and CSF glucose levels (<italic>r</italic>&#x2009;=&#x2009;&#x2212;0.506; <italic>p</italic>&#x2009;=&#x2009;0.047).</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion" id="sec21">
<label>4</label>
<title>Discussion</title>
<p>Despite the relatively low prevalence of HIV co-infection among pediatric meningitis suspects in the hospital setting (<xref ref-type="bibr" rid="ref51">Solomons et al., 2016</xref>), this study provides a rare opportunity to investigate the influence of HIV on the CNS compartment in perinatally infected children. The brain microenvironment is metabolically unique due to the strict regulation of metabolite exchange by the BBB. Regulation of brain metabolism is crucial, especially during early life, when energy demands for brain growth and plasticity are exceedingly high and can account for up to 44% of the metabolic rate and substrate requirements of the body (<xref ref-type="bibr" rid="ref38">Oyarz&#x00E1;bal et al., 2021</xref>). Fine-tuning metabolism in the brain is essential for maintaining energy homeostasis, supporting neuronal functions, protecting against oxidative stress, and facilitating communication within the nervous system. The findings of our study show the complex metabolic dynamics within the CNS of HIV-infected children, and the altered neurometabolism due to the aberrations of the underlying cellular processes induced by HIV infection. By delineating potential pathways of metabolic flux and cellular interactions, we aim to elucidate the changes in the neuroenergetics of pediatric HIV patients, which subsequently lead to the associated neurocognitive symptoms.</p>
<sec id="sec22">
<label>4.1</label>
<title>Perturbed neuroenergetics in HIV</title>
<p>In this study, we found decreased levels of glucose and increased levels of lactate in the CSF of the HIV-infected participants, comparatively. Individually, these two metabolites were not statistically significant; however, the lactate:glucose ratio (<xref ref-type="table" rid="tab3">Table 3</xref>) in the HIV+ group (0.81&#x2009;&#x00B1;&#x2009;0.23) was significantly higher (<italic>p</italic>&#x2009;=&#x2009;0.008) than the controls (0.64&#x2009;&#x00B1;&#x2009;0.13), indicating an elevated flux through glycolysis toward lactate production (i.e., higher rate of glycolysis). Current literature suggests increased glycolysis in all HIV-infected cells, including microglia and infiltrating immune cells, which promotes the production and secretion of immune mediators that activate astrocytes and increase glycolysis in this cell type. The lactate:pyruvate ratios, however, were unchanged in the HIV+ group (53.71&#x2009;&#x00B1;&#x2009;25.44) compared to the controls (54.26&#x2009;&#x00B1;&#x2009;26.81), suggesting unaltered cytosolic NADH:NAD ratios. However, an increased mitochondrial redox potential [significantly lower (<italic>p</italic>&#x2009;=&#x2009;0.030) 3-hydroxybutyrate:acetoacetate ratios in the HIV+ group (0.73&#x2009;&#x00B1;&#x2009;0.60) compared to the controls (2.20&#x2009;&#x00B1;&#x2009;2.58)] indicates elevated mitochondrial activity in the HIV+ group. As there is a persistent activation of the immune response in HIV, increased mitochondrial activity is likely localized to the microglia, as astrocytes are predominantly glycolytic (<xref ref-type="bibr" rid="ref32">Magistretti and Allaman, 2018</xref>). However, a calcium overload in the neurons, induced by astrocyte dysfunction and oxidative damage, also likely triggers increased tricarboxylic acid (TCA) cycle activity. Significantly decreased ketones (acetone and 3-hydroxybutyrate) in the HIV+ group in this study are consistent with the findings of <xref ref-type="bibr" rid="ref25">Keram et al. (2021)</xref> and <xref ref-type="bibr" rid="ref12">Deme et al. (2022)</xref>, but in contrast to the results of <xref ref-type="bibr" rid="ref6">Cassol et al. (2014)</xref>. The significantly elevated (<italic>p</italic>&#x2009;=&#x2009;0.049) myo-inositol levels (590.64&#x2009;&#x00B1;&#x2009;509.20) detected in the CSF of the HIV+ group, compared to the controls (244.82&#x2009;&#x00B1;&#x2009;107.37) is indicative of astrocyte activation. While the exact mechanism for cellular interactions cannot be ascertained from this study alone, we hypothesize that astrocyte-derived lactate is being shuttled into the microglial cells [astrocyte&#x2013;microglial lactate shuttle (AMLS); <xref ref-type="bibr" rid="ref33">Mason, 2017</xref>] where it is utilized for energy production to support the persistent immune response known to occur in HIV patients. Hence, the increased flux of neuroenergetics may be channeled via astrocytes to microglia, inhibiting the usual energy shuttle to the neurons. This reduced flux of neuroenergetics toward the neurons could be due to a host-induced neuroprotective mechanism preventing oxidative damage to neurons. It is well known that HIV viral replication yields high amounts of reactive oxygen species (ROS), which subsequently leads to a depletion of intracellular reduced glutathione (GSH) (<xref ref-type="bibr" rid="ref42">Perl and Banki, 2004</xref>). Re-synthesis of GSH consumes methionine, eventually depleting this metabolite, which, in turn, impairs GSH production, as is demonstrated by the reduced concentrations of 2-hydroxybutyrate in the HIV+ group comparatively, which forms as a by-product of this biosynthetic pathway. Reduced neuronal activity, evidenced by the higher levels of glutamine in the CSF of the HIV+ group comparatively, agrees with the reduced neurocognitive activity associated with HAND (<xref ref-type="bibr" rid="ref17">Gleichmann and Mattson, 2011</xref>; <xref ref-type="bibr" rid="ref22">Irollo et al., 2021</xref>). <xref ref-type="fig" rid="fig3">Figure 3</xref> illustrates our hypothesized metabolic model, based on these results, of the perturbed neuroenergetics associated with the persistent immune activation in the brain of pediatric HIV patients.</p>
<fig position="float" id="fig3">
<label>Figure 3</label>
<caption>
<p>Hypothesized metabolic model of perturbed neuroenergetics in CSF samples collected from pediatric patients with HIV. AMLS, astrocyte-microglia lactate shuttle; LAC, lactate; ROS, reactive oxygen species; GSH, reduced glutathione (created with <ext-link xlink:href="http://BioRender.com" ext-link-type="uri">BioRender.com</ext-link>).</p>
</caption>
<graphic xlink:href="fnins-18-1270041-g003.tif"/>
</fig>
</sec>
<sec id="sec23">
<label>4.2</label>
<title>Support of our hypothesized model from the literature</title>
<p>In this pediatric HIV-infected cohort, we observed elevated glycolytic pathway activity indicated by the high lactate:glucose ratio. Abnormalities in glucose metabolism are a well-documented occurrence in HIV participants (<xref ref-type="bibr" rid="ref49">Sinharay and Hammoud, 2019</xref>; <xref ref-type="bibr" rid="ref12">Deme et al., 2022</xref>). Increased glycolytic rate in virally suppressed adults and perinatally infected children correlates with worsening cognitive status (<xref ref-type="bibr" rid="ref13">Dickens et al., 2015</xref>; <xref ref-type="bibr" rid="ref24">Kaur et al., 2020</xref>). It is likely that the increased glycolytic rate, associated with the decline in cognitive ability in virally suppressed patients, is due to continued immune activation in the CNS compartment (<xref ref-type="bibr" rid="ref12">Deme et al., 2022</xref>). Immune activation coupled with high biosynthetic and energetic demands requires extensive metabolic reprogramming (<xref ref-type="bibr" rid="ref48">Shehata et al., 2017</xref>; <xref ref-type="bibr" rid="ref5">Caslin et al., 2021</xref>). In conjunction with increased nutrient uptake, there is a considerable rise in glycolysis, despite sufficient oxygen levels, which is then used to fuel the biosynthetic pathways that produce the nucleotides and precursors for lipid and amino acid biosynthesis, which, in turn, allow for robust cell growth and proliferation (<xref ref-type="bibr" rid="ref48">Shehata et al., 2017</xref>).</p>
<p><xref ref-type="bibr" rid="ref8">Clerc et al. (2019)</xref> indicated that glucose metabolism impacts the vulnerability of CD4+ T cells to HIV infection. The glucose transporter (GLUT-1) is upregulated on HIV-infected CD4+ T cells and required for cellular activation, the metabolic shift from oxidative phosphorylation (OXPHOS) to aerobic glycolysis, and consequently its effector functions (<xref ref-type="bibr" rid="ref40">Palmer et al., 2016</xref>; <xref ref-type="bibr" rid="ref48">Shehata et al., 2017</xref>; <xref ref-type="bibr" rid="ref8">Clerc et al., 2019</xref>). Furthermore, high glucose uptake increases the expression of CXCR4 and CCR5, co-receptors required for HIV entry into a cell (<xref ref-type="bibr" rid="ref40">Palmer et al., 2016</xref>; <xref ref-type="bibr" rid="ref8">Clerc et al., 2019</xref>). This vulnerability may also partly be attributed to the activation of the mechanistic target of the rapamycin (mTOR) pathway as mTOR-complex 1 (mTORC1) upregulates CCR5 expression, while mTOR-complex 2 (mTORC2) leads to the induction of HIV transcription (<xref ref-type="bibr" rid="ref40">Palmer et al., 2016</xref>; <xref ref-type="bibr" rid="ref48">Shehata et al., 2017</xref>; <xref ref-type="bibr" rid="ref8">Clerc et al., 2019</xref>). The HIV protein transactivator of transcription (tat) hyperactivates mTORC1 activity (<xref ref-type="bibr" rid="ref48">Shehata et al., 2017</xref>). Moreover, HIV exacerbates the glycolytic shift in activated T cells and macrophages by upregulating the expression of glycolytic enzymes including glucose-6-phosphate dehydrogenase (G6PDH), hexokinase (HK), and pyruvate kinase M2 (PKM2) to highjack the cellular processes for virion production (<xref ref-type="bibr" rid="ref3">Barrero et al., 2013</xref>; <xref ref-type="bibr" rid="ref48">Shehata et al., 2017</xref>; <xref ref-type="bibr" rid="ref12">Deme et al., 2022</xref>). It is possible that dysregulation of immune cell metabolism, including excessive uptake of glucose, might induce hyperactivation of the immune system and contribute to HIV pathogenesis (<xref ref-type="bibr" rid="ref40">Palmer et al., 2016</xref>; <xref ref-type="bibr" rid="ref12">Deme et al., 2022</xref>).</p>
<p>This study found further evidence of altered neuroenergetics indicated by the decreased levels of ketone bodies in the CSF of this HIV+ group. During prolonged fasting periods, diabetes, and neonatal or pre-weaning development, the brain becomes dependent on ketone bodies for energy production (<xref ref-type="bibr" rid="ref11">Deme et al., 2020</xref>). The lower 3-hydroxybutyrate:acetoacetate ratio indicates elevated mitochondrial activity in the HIV+ group. As there is a persistent activation of the immune response in HIV, increased mitochondrial activity is likely localized to the microglia as astrocytes are predominantly glycolytic (<xref ref-type="bibr" rid="ref32">Magistretti and Allaman, 2018</xref>). Furthermore, in HIV-infected cells acetyl-CoA is also directed toward fatty acid synthesis, via increased fatty acid synthase activity, thereby further reducing the downstream formation of ketone bodies (<xref ref-type="bibr" rid="ref27">Kulkarni et al., 2017</xref>). Fatty acid synthase produces longer chain fatty acids, which are required for the generation of lipid micro-domains essential for viral budding or to produce fatty acyl adducts, which are necessary for post-translational modification of viral proteins such as Env, Gag, and Nef (<xref ref-type="bibr" rid="ref27">Kulkarni et al., 2017</xref>; <xref ref-type="bibr" rid="ref12">Deme et al., 2022</xref>). Moreover, Vpr reduces transcription of acetyl-CoA acetyltransferase in macrophages, which encodes for mitochondrial acetoacetyl-CoA thiolase, the enzyme that converts two units of acetyl-CoA to acetoacetyl-CoA, for ketone body production (<xref ref-type="bibr" rid="ref3">Barrero et al., 2013</xref>). Therefore, successful suppression of viral replication by ART use has been shown to normalize ketone body serum levels (<xref ref-type="bibr" rid="ref12">Deme et al., 2022</xref>). Beyond being substrates for neuronal ATP synthesis, ketone bodies have a variety of paracrine and autocrine signaling functions that alter gene expression, lipid metabolism, neuronal function, and metabolic rate (<xref ref-type="bibr" rid="ref36">Newman and Verdin, 2017</xref>). Tissue culture experiments found that the treatment of neurons with ketone bodies protects these cells against tat-induced oxidative stress and calcium-induced hyperexcitability (<xref ref-type="bibr" rid="ref26">Kim et al., 2010</xref>; <xref ref-type="bibr" rid="ref21">Hui et al., 2012</xref>; <xref ref-type="bibr" rid="ref16">Garcia-Rodriguez and Gimenez-Cassina, 2021</xref>). Ketone body utilization also produces high levels of ATP and can stimulate mitochondrial biogenesis (<xref ref-type="bibr" rid="ref21">Hui et al., 2012</xref>). Considering the various regulatory and protective functions that ketone bodies are known to exert in the CNS, dysregulation of ketone body metabolism in children infected with HIV is likely to contribute to the pathology of HIV infection and the brain abnormalities observed in this population. The long-term effects of aberration of ketone body metabolism, as it occurs during critical developmental stages, need further investigation. Our study found reduced levels of 2-hydroxybutyrate in the HIV+ group comparatively, indicating exhaustion of the antioxidant systems. HIV replication exacerbates oxidative damage in the CNS compartment by reducing intracellular GSH levels and modulating the transcription of several enzymes involved in GSH metabolism (<xref ref-type="bibr" rid="ref43">Porcheray et al., 2006</xref>). When GSH becomes depleted, methionine and cysteine are both directed toward its re-synthesis through the sequence of reactions, methionine &#x003E; cystathionine &#x003E; cysteine &#x003E; GSH (<xref ref-type="bibr" rid="ref30">Lertratanangkoon et al., 1996</xref>). During the conversion of cystathionine to cysteine, 2-ketobutyrate is produced and then reduced to 2-hydroxybutyrate (<xref ref-type="bibr" rid="ref29">Legault et al., 2015</xref>). Other studies have reported methionine deficiencies in ART-na&#x00EF;ve adults and children with HIV, which would also result in the reduced formation of 2-hydroxybutyrate, but these levels are corrected with ART (<xref ref-type="bibr" rid="ref24">Kaur et al., 2020</xref>; <xref ref-type="bibr" rid="ref12">Deme et al., 2022</xref>). Our findings indicate an inability to control oxidative stress levels in the CNS compartment of children with HIV.</p>
<p>ROS can also function as signaling molecules and contribute to neuronal development and function. ROS mediates various functions within the nervous system via the glial cells and glial-neuron interactions (<xref ref-type="bibr" rid="ref37">Oswald et al., 2018</xref>). Myo-inositol, elevated in the CSF of the HIV+ group in our study, is a marker of astrocyte activation (<xref ref-type="bibr" rid="ref6">Cassol et al., 2014</xref>; <xref ref-type="bibr" rid="ref13">Dickens et al., 2015</xref>; <xref ref-type="bibr" rid="ref24">Kaur et al., 2020</xref>). Gliosis, a characteristic of the chronic neuroinflammation induced by HIV, persists despite ART (<xref ref-type="bibr" rid="ref24">Kaur et al., 2020</xref>). Previous studies have associated higher CSF myo-inositol levels with a decline in cognitive function, even in virally suppressed HIV patients (<xref ref-type="bibr" rid="ref14">Ernst et al., 2003</xref>; <xref ref-type="bibr" rid="ref20">Harezlak et al., 2011</xref>; <xref ref-type="bibr" rid="ref6">Cassol et al., 2014</xref>; <xref ref-type="bibr" rid="ref57">Williams et al., 2021a</xref>). Other studies have also confirmed abnormalities in myo-inositol metabolism in children infected with HIV, particularly in the left frontal brain region (<xref ref-type="bibr" rid="ref24">Kaur et al., 2020</xref>). The intracellular concentrations of myo-inositol are influenced by several processes, including uptake, biosynthesis, recycling from derivatives, degradation, and efflux (<xref ref-type="bibr" rid="ref10">Croze and Soulage, 2013</xref>). Considering the latter, increased efflux due to cell swelling results in the depletion of intracellular myo-inositol. This decrease in intracellular myo-inositol levels impairs phosphoinositide (PI) signaling, disrupting the intracellular calcium balance, resulting in neuronal hyperexcitability, and causing deficiencies in neurotransmitter release and ion conductivity (<xref ref-type="bibr" rid="ref10">Croze and Soulage, 2013</xref>).</p>
<p>We hypothesize that alterations in PI turnover contribute to the impairment of neuronal activity. Patients with moderate-to-severe HAND present with reduced synaptic transmission (<xref ref-type="bibr" rid="ref22">Irollo et al., 2021</xref>). Disruption of PI signaling is associated with reduced Na<sup>+</sup>/K<sup>+</sup>-ATPase activity, leading to impaired nerve conduction (<xref ref-type="bibr" rid="ref28">Lang et al., 1998</xref>; <xref ref-type="bibr" rid="ref15">Fisher et al., 2002</xref>; <xref ref-type="bibr" rid="ref10">Croze and Soulage, 2013</xref>). The disruption of calcium signaling and homeostasis, induced by altered PI signaling, is augmented by high ROS levels that cause oxidative damage to the mitochondria reducing its buffering capacity, thereby increasing the susceptibility to excitotoxicity (<xref ref-type="bibr" rid="ref17">Gleichmann and Mattson, 2011</xref>). In response, neurons can initiate a homeostatic adaptation called synaptic scaling (<xref ref-type="bibr" rid="ref19">Green et al., 2019</xref>), which aims to rebalance excitatory and inhibitory synaptic transmission, typically resulting in a de-potentiation of excitatory synapses and a heightened inhibitory transmission in HAND models (<xref ref-type="bibr" rid="ref17">Gleichmann and Mattson, 2011</xref>; <xref ref-type="bibr" rid="ref19">Green et al., 2019</xref>). Support for this hypothesis comes from the viral protein, tat, which has been shown to alter intracellular calcium levels via the inositol-1,4,5-trisphosphate (IP3) receptor (IP3R) in rat hippocampal neurons (<xref ref-type="bibr" rid="ref9">Cotto et al., 2019</xref>). With chronically high ROS levels, energy production will eventually diminish, and neurons will become prone to excitotoxicity (<xref ref-type="bibr" rid="ref17">Gleichmann and Mattson, 2011</xref>).</p>
<p>Accumulation of glutamine in the CSF of our HIV+ cohort suggests altered neural activity. Astrocytes regulate glutamatergic and GABAergic neurotransmission through the activity of the glutamate-glutamine cycle, which can be dysregulated by both a pro-inflammatory environment and HIV proteins (<xref ref-type="bibr" rid="ref7">Chaudhry et al., 2002</xref>; <xref ref-type="bibr" rid="ref54">Vazquez-Santiago et al., 2014</xref>; <xref ref-type="bibr" rid="ref2">Bairwa et al., 2016</xref>; <xref ref-type="bibr" rid="ref33">Mason, 2017</xref>; <xref ref-type="bibr" rid="ref22">Irollo et al., 2021</xref>). The balanced cycling of glutamate and glutamine is essential for normal neuronal function (<xref ref-type="bibr" rid="ref2">Bairwa et al., 2016</xref>). Several studies have reported significantly decreased GABAergic markers in brain samples from HIV-infected participants with and without HAND and have found correlations with neuroimmune markers in the brain (<xref ref-type="bibr" rid="ref4">Borjabad and Volsky, 2012</xref>; <xref ref-type="bibr" rid="ref22">Irollo et al., 2021</xref>). GABAergic signaling is involved in neuronal proliferation, migration, differentiation, preliminary circuit-building, the formation of interstitial neurons in the white matter, and the development of oligodendrocytes (<xref ref-type="bibr" rid="ref58">Wu and Sun, 2015</xref>). Disruption of GABAergic signaling may be a contributing factor to the white matter abnormalities often associated with HIV infection (<xref ref-type="bibr" rid="ref22">Irollo et al., 2021</xref>). Moreover, abnormal excitatory glutamate neurotransmission has long been reported in HAND patients (<xref ref-type="bibr" rid="ref22">Irollo et al., 2021</xref>). Glutamatergic neurotransmissions are involved in synaptic plasticity, learning and memory, and mood regulation (<xref ref-type="bibr" rid="ref31">Madeira et al., 2018</xref>). Therefore, the long-term consequences of altered glutamate-glutamine cycling could be severe and possibly contribute to the development of HAND (<xref ref-type="bibr" rid="ref31">Madeira et al., 2018</xref>). We hypothesize that aberration of myo-inositol metabolism and high ROS levels could contribute to the reduced neuronal activity observed in HAND (<xref ref-type="bibr" rid="ref4">Borjabad and Volsky, 2012</xref>; <xref ref-type="bibr" rid="ref22">Irollo et al., 2021</xref>), by dysregulating calcium homeostasis, leading to activation of compensatory mechanisms that function to counteract excitotoxicity (<xref ref-type="bibr" rid="ref19">Green et al., 2019</xref>). The result is reduced rates of glutamine uptake in the neurons and subsequently elevated glutamine in the CSF of the HIV+ group.</p>
<p>In our study, the positive correlation of glutamine with 2-hydroxybutyrate suggests that glutamine may be increased due to a compensatory mechanism that lowers neural synaptic activity to reduce ROS production, reducing the requirement for GSH synthesis. 2-Hydroxybutyric acid also correlated with fever, CSF protein, and meningeal irritation, suggesting that high ROS levels cause damage to the BBB. The increased glycolytic rate in astrocytes would also drive the glutamate to glutamine conversion in these cells (<xref ref-type="bibr" rid="ref33">Mason, 2017</xref>), possibly explaining the correlation of glutamine with viral count. Glutamine also correlated with meningeal irritation and vomiting, which may be another consequence of increased viral replication and astrocyte activation as HIV is known to disrupt the integrity of the BBB (<xref ref-type="bibr" rid="ref34">McArthur and Johnson, 2020</xref>). Astrocytes are critical structural components of the BBB; hence, astrocyte activation and disruption of their normal cellular function diminish the integrity of the BBB, leading to meningeal irritation, indicated by the correlation of this clinical feature as well as CSF protein levels with myo-inositol. The positive correlation of myo-inositol with glutamine may confirm that altered PI signaling interferes with neuronal activity. Further investigation is required to confirm or refute this hypothesis.</p>
<p>As astrocytes form an integral part of the BBB, they act as a cellular barrier between the blood and neurons (<xref ref-type="bibr" rid="ref41">Pellerin, 2010</xref>). Astrocytes play a crucial role in supporting neuronal activity, not just by recycling neurotransmitters but also because the uptake of glutamate stimulates an increase in glucose uptake, glycolysis, and lactate production, which are released into the extracellular space, in response to synaptic activity, in order accommodate the energy demands of these neurons. This model has been termed the astrocyte&#x2013;neuron lactate shuttle (ANLS) hypothesis (<xref ref-type="bibr" rid="ref33">Mason, 2017</xref>). Under conditions of sustained physiological challenges, such as in HIV, the astrocyte&#x2013;microglia lactate shuttle (AMLS) hypothesis suggests that brain energy metabolism shifts away from neurons to provide lactate to activated microglia in support of the immune response (<xref ref-type="bibr" rid="ref33">Mason, 2017</xref>). Lactate modulates several key microglia features, including proliferation, migration, and phagocytosis (<xref ref-type="bibr" rid="ref35">Monsorno et al., 2022</xref>). Within microglia, lactate enters the TCA cycle and electron transport chain to produce ATP and the ROS necessary for eliminating invading pathogens (<xref ref-type="bibr" rid="ref33">Mason, 2017</xref>; <xref ref-type="bibr" rid="ref35">Monsorno et al., 2022</xref>). Further investigation is required to confirm or refute this AMLS hypothesis.</p>
<p>In our study, an additional source of lactate would be via the increased concentrations of 1,2-propanediol, also previously associated with HAND in adults infected with HIV (<xref ref-type="bibr" rid="ref6">Cassol et al., 2014</xref>). 1,2-propanediol, found to be elevated in this HIV+ group, functions as a solvent in a variety of intravenously administered medications and may originate from higher medication usage in the HIV+ group comparatively. Endogenous sources, however, include dihydroxyacetone phosphate metabolism or acetone breakdown (<xref ref-type="bibr" rid="ref45">Ruddick, 1972</xref>). Viral protein R (Vpr) reduces the expression of triosephosphate isomerase (TPI) in macrophages to direct more glucose to the PPP (<xref ref-type="bibr" rid="ref3">Barrero et al., 2013</xref>). The downregulation of TPI in the frontal cortex of HIV patients is associated with neurodegeneration (<xref ref-type="bibr" rid="ref60">Zhou et al., 2010</xref>). This leads to the accumulation of dihydroxyacetone phosphate, which is eventually metabolized to 1,2-propanediol.</p>
</sec>
<sec id="sec24">
<label>4.3</label>
<title>Correlations</title>
<p>The correlations between the metabolites improve our understanding of the interplay between the discussed pathways. Glucose correlated with lactate and metabolites related to ketone body metabolism. We expected this as all these metabolic pathways are directed toward energy production, intersecting at the TCA cycle. Furthermore, mTOR activity regulates both glycolysis and ketogenesis. The positive correlation between glucose and metabolites of ketone body metabolism, which were both lower in the HIV+ group, suggests the utilization of these metabolites to meet the increased energy demand of an HIV-infected brain. In the study by <xref ref-type="bibr" rid="ref12">Deme et al. (2022)</xref>, higher serum methionine levels, and by extension higher 2-hydroxybutyrate levels, correlated with higher CD4+ T counts in treatment-na&#x00EF;ve adults with HIV, indicating its role in the control of viral replication. Hence, this might also explain the positive correlation of glucose with 2-hydroxybutyrate as higher rates of viral replication would lead to higher ROS production, decreasing methionine levels, increasing activation of the glycolytic pathway, and decreasing CSF glucose levels (<xref ref-type="bibr" rid="ref30">Lertratanangkoon et al., 1996</xref>; <xref ref-type="bibr" rid="ref48">Shehata et al., 2017</xref>).</p>
<p>Reduced CSF glucose levels are an indicator of increased immune activation in the CNS compartment, supporting the positive correlation between glucose and fever (<xref ref-type="bibr" rid="ref48">Shehata et al., 2017</xref>). The positive correlation of lactate with the CSF lymphocyte counts suggests that this metabolite originates from immune activation or viral replication (<xref ref-type="bibr" rid="ref39">Pajkrt et al., 2016</xref>). 3-Hydroxybuturate positively correlated with acetone, fever, and viral count, suggesting that ketone body metabolism supports viral replication by increasing the activity of the TCA cycle, which is known to promote virion production (<xref ref-type="bibr" rid="ref3">Barrero et al., 2013</xref>). The positive correlations of 3-hydroxybutyrate and acetone with glutamine and 2-hydroxybutyrate suggest increased viral replication results in oxidative stress, which subsequently leads to increased GSH synthesis, marked by elevated 2-hydroxybutyrate and the initiation of a protective mechanism that reduces neural activity, increasing extracellular glutamine (<xref ref-type="bibr" rid="ref30">Lertratanangkoon et al., 1996</xref>; <xref ref-type="bibr" rid="ref17">Gleichmann and Mattson, 2011</xref>; <xref ref-type="bibr" rid="ref22">Irollo et al., 2021</xref>). Similarly, the positive correlation of acetone with 2-hydroxybutyrate may signify an increased requirement for GSH due to oxidative stress induced by HIV viral replication (<xref ref-type="bibr" rid="ref42">Perl and Banki, 2004</xref>).</p>
<p>Alterations in brain energy metabolism are apparent already in the early stages of disease following HIV infection and do not fully normalize even after successful viral suppression (<xref ref-type="bibr" rid="ref11">Deme et al., 2020</xref>). Our research group and others have observed that HIV induces changes to the host&#x2019;s cell metabolism to hyperactivate glycolysis, augments lactate production, and increases the flux through the PPP, decreasing &#x03B2;-oxidation of long-chain fatty acids and increasing amino acid catabolism (<xref ref-type="bibr" rid="ref12">Deme et al., 2022</xref>). Furthermore, similar metabolic changes in the brain&#x2019;s energy metabolism have been associated with several other neurodegenerative diseases, including HAND, and also resemble age-related mechanisms of pathogenesis (<xref ref-type="bibr" rid="ref6">Cassol et al., 2014</xref>; <xref ref-type="bibr" rid="ref11">Deme et al., 2020</xref>).</p>
</sec>
<sec id="sec25">
<label>4.4</label>
<title>Limitations and strengths</title>
<p>Several limitations exist in this study, such as the limited number of HIV+ samples available, a control group that was not entirely healthy, and the absence of a validation cohort. However, the importance is to recognize that these limitations are not easily surmountable given that the study&#x2019;s focus is on a pediatric patient population and that CSF samples, rare to obtain, were used. Few studies have investigated CSF in pediatric HIV cases, making this study unique and its findings extremely valuable. As this study was holistic and exploratory in nature, we subsequently identified several new metabolite markers for HIV in a pediatric population, which not only provides numerous new biochemical hypotheses to direct future studies but also supports existing hypotheses or conclusions made by other groups. The hypothesized metabolic model proposed here requires further scientific engagements to support or refute our hypotheses.</p>
</sec>
</sec>
<sec sec-type="conclusions" id="sec26">
<label>5</label>
<title>Conclusion</title>
<p>The results of this study confirm previous findings that HIV dysregulates cellular metabolic processes, including upregulating glycolysis, dysregulating ketone body metabolism, and increasing ROS production. These changes relate to the increased metabolic demand associated with immune activation and high viral replication. We hypothesize that neuroinflammation alters astrocyte-neuron communication and lowers neuronal activity in children infected with HIV, which, in turn, may contribute to the neurodevelopmental delay often observed in this population.</p>
</sec>
<sec sec-type="data-availability" id="sec27">
<title>Data availability statement</title>
<p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p>
</sec>
<sec sec-type="ethics-statement" id="sec28">
<title>Ethics statement</title>
<p>The studies involving humans were approved by the Health Research Ethics Committee (HREC) of Stellenbosch University, Tygerberg Hospital (ethics approval no. N16/11/142), and the HREC of the North-West University (NWU), Potchefstroom campus (ethics approval no. NWU-00063-18-A1). The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants&#x2019; legal guardians/next of kin.</p>
</sec>
<sec sec-type="author-contributions" id="sec29">
<title>Author contributions</title>
<p>AT: Data curation, Formal analysis, Investigation, Methodology, Writing &#x2013; original draft. DL: Formal analysis, Funding acquisition, Resources, Supervision, Writing &#x2013; review &#x0026; editing. MW: Formal analysis, Resources, Supervision, Writing &#x2013; review &#x0026; editing. RS: Data curation, Investigation, Writing &#x2013; review &#x0026; editing. SM: Conceptualization, Data curation, Formal analysis, Methodology, Project administration, Resources, Supervision, Writing &#x2013; review &#x0026; editing.</p>
</sec>
</body>
<back>
<sec sec-type="funding-information" id="sec30">
<title>Funding</title>
<p>The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. MW was funded by the NRF Thuthuka grant (TTK22031652) and the Poliomyelitis Research Foundation (PRF) grant (23/84).</p>
</sec>
<ack>
<p>We acknowledge the analytical assistance offered by Tiaan van Zyl and advice given on the statistical analyses by Dr. Mari van Reenen, both from the Centre for Human Metabolomics at the Potchefstroom campus of North-West University.</p>
</ack>
<sec sec-type="COI-statement" id="sec31">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="sec100" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec sec-type="supplementary-material" id="sec32">
<title>Supplementary material</title>
<p>The Supplementary material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fnins.2024.1270041/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fnins.2024.1270041/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Image_1.pdf" id="SM1" mimetype="application/pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="ref1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Antinori</surname> <given-names>A.</given-names></name> <name><surname>Arendt</surname> <given-names>G.</given-names></name> <name><surname>Becker</surname> <given-names>J. T.</given-names></name> <name><surname>Brew</surname> <given-names>B. J.</given-names></name> <name><surname>Byrd</surname> <given-names>D. A.</given-names></name> <name><surname>Cherner</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2007</year>). <article-title>Updated research nosology for HIV-associated neurocognitive disorders</article-title>. <source>Neurology</source> <volume>69</volume>, <fpage>1789</fpage>&#x2013;<lpage>1799</lpage>. doi: <pub-id pub-id-type="doi">10.1212/01.WNL.0000287431.88658.8b</pub-id>, PMID: <pub-id pub-id-type="pmid">17914061</pub-id></citation></ref>
<ref id="ref2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bairwa</surname> <given-names>D.</given-names></name> <name><surname>Kumar</surname> <given-names>V.</given-names></name> <name><surname>Vyas</surname> <given-names>S.</given-names></name> <name><surname>Das</surname> <given-names>B. K.</given-names></name> <name><surname>Srivastava</surname> <given-names>A. K.</given-names></name> <name><surname>Pandey</surname> <given-names>R. M.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Case control study: magnetic resonance spectroscopy of brain in HIV infected patients</article-title>. <source>BMC Neurol.</source> <volume>16</volume>:<fpage>99</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12883-016-0628-x</pub-id>, PMID: <pub-id pub-id-type="pmid">27405321</pub-id></citation></ref>
<ref id="ref3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barrero</surname> <given-names>C. A.</given-names></name> <name><surname>Datta</surname> <given-names>P. K.</given-names></name> <name><surname>Sen</surname> <given-names>S.</given-names></name> <name><surname>Deshmane</surname> <given-names>S.</given-names></name> <name><surname>Amini</surname> <given-names>S.</given-names></name> <name><surname>Khalili</surname> <given-names>K.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>HIV-1 Vpr modulates macrophage metabolic pathways: a SILAC-based quantitative analysis</article-title>. <source>PLoS One</source> <volume>8</volume>:<fpage>e68376</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0068376</pub-id>, PMID: <pub-id pub-id-type="pmid">23874603</pub-id></citation></ref>
<ref id="ref4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Borjabad</surname> <given-names>A.</given-names></name> <name><surname>Volsky</surname> <given-names>D. J.</given-names></name></person-group> (<year>2012</year>). <article-title>Common transcriptional signatures in brain tissue from patients with HIV-associated neurocognitive disorders, Alzheimer's disease, and multiple sclerosis</article-title>. <source>J. Neuroimmune Pharmacol.</source> <volume>7</volume>, <fpage>914</fpage>&#x2013;<lpage>926</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11481-012-9409-5</pub-id></citation></ref>
<ref id="ref5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caslin</surname> <given-names>H. L.</given-names></name> <name><surname>Abebayehu</surname> <given-names>D.</given-names></name> <name><surname>Pinette</surname> <given-names>J. A.</given-names></name> <name><surname>Ryan</surname> <given-names>J. J.</given-names></name></person-group> (<year>2021</year>). <article-title>Lactate is a metabolic mediator that shapes immune cell fate and function</article-title>. <source>Front. Physiol.</source> <volume>12</volume>:<fpage>688485</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fphys.2021.688485</pub-id>, PMID: <pub-id pub-id-type="pmid">34733170</pub-id></citation></ref>
<ref id="ref6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cassol</surname> <given-names>E.</given-names></name> <name><surname>Misra</surname> <given-names>V.</given-names></name> <name><surname>Dutta</surname> <given-names>A.</given-names></name> <name><surname>Morgello</surname> <given-names>S.</given-names></name> <name><surname>Gabuzda</surname> <given-names>D.</given-names></name></person-group> (<year>2014</year>). <article-title>Cerebrospinal fluid metabolomics reveals altered waste clearance and accelerated aging in HIV patients with neurocognitive impairment</article-title>. <source>AIDS</source> <volume>28</volume>, <fpage>1579</fpage>&#x2013;<lpage>1591</lpage>. doi: <pub-id pub-id-type="doi">10.1097/QAD.0000000000000303</pub-id>, PMID: <pub-id pub-id-type="pmid">24752083</pub-id></citation></ref>
<ref id="ref7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chaudhry</surname> <given-names>F. A.</given-names></name> <name><surname>Schmitz</surname> <given-names>D.</given-names></name> <name><surname>Reimer</surname> <given-names>R. J.</given-names></name> <name><surname>Larsson</surname> <given-names>P.</given-names></name> <name><surname>Gray</surname> <given-names>A. T.</given-names></name> <name><surname>Nicoll</surname> <given-names>R.</given-names></name> <etal/></person-group>. (<year>2002</year>). <article-title>Glutamine uptake by neurons: interaction of protons with system a transporters</article-title>. <source>J. Neurosci.</source> <volume>22</volume>, <fpage>62</fpage>&#x2013;<lpage>72</lpage>. doi: <pub-id pub-id-type="doi">10.1523/JNEUROSCI.22-01-00062.2002</pub-id>, PMID: <pub-id pub-id-type="pmid">11756489</pub-id></citation></ref>
<ref id="ref8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clerc</surname> <given-names>I.</given-names></name> <name><surname>Moussa</surname> <given-names>D. A.</given-names></name> <name><surname>Vahlas</surname> <given-names>Z.</given-names></name> <name><surname>Tardito</surname> <given-names>S.</given-names></name> <name><surname>Oburoglu</surname> <given-names>L.</given-names></name> <name><surname>Hope</surname> <given-names>T. J.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Entry of glucose- and glutamine-derived carbons into the citric acid cycle supports early steps of HIV-1 infection in CD4 T cells</article-title>. <source>Nat. Metab.</source> <volume>1</volume>, <fpage>717</fpage>&#x2013;<lpage>730</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s42255-019-0084-1</pub-id>, PMID: <pub-id pub-id-type="pmid">32373781</pub-id></citation></ref>
<ref id="ref9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cotto</surname> <given-names>B.</given-names></name> <name><surname>Natarajanseenivasan</surname> <given-names>K.</given-names></name> <name><surname>Langford</surname> <given-names>D.</given-names></name></person-group> (<year>2019</year>). <article-title>HIV-1 infection alters energy metabolism in the brain: contributions to HIV-associated neurocognitive disorders</article-title>. <source>Prog. Neurobiol.</source> <volume>181</volume>:<fpage>101616</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.pneurobio.2019.101616</pub-id>, PMID: <pub-id pub-id-type="pmid">31108127</pub-id></citation></ref>
<ref id="ref10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Croze</surname> <given-names>M. L.</given-names></name> <name><surname>Soulage</surname> <given-names>C. O.</given-names></name></person-group> (<year>2013</year>). <article-title>Potential role and therapeutic interests of myo-inositol in metabolic diseases</article-title>. <source>Biochimie</source> <volume>95</volume>, <fpage>1811</fpage>&#x2013;<lpage>1827</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.biochi.2013.05.011</pub-id>, PMID: <pub-id pub-id-type="pmid">23764390</pub-id></citation></ref>
<ref id="ref11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deme</surname> <given-names>P.</given-names></name> <name><surname>Rojas</surname> <given-names>C.</given-names></name> <name><surname>Slusher</surname> <given-names>B. S.</given-names></name> <name><surname>Rais</surname> <given-names>R.</given-names></name> <name><surname>Afghah</surname> <given-names>Z.</given-names></name> <name><surname>Geiger</surname> <given-names>J. D.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Bioenergetic adaptations to HIV infection. Could modulation of energy substrate utilization improve brain health in people living with HIV-1?</article-title> <source>Exp. Neurol.</source> <volume>327</volume>:<fpage>113181</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.expneurol.2020.113181</pub-id>, PMID: <pub-id pub-id-type="pmid">31930991</pub-id></citation></ref>
<ref id="ref12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deme</surname> <given-names>P.</given-names></name> <name><surname>Rubin</surname> <given-names>L. H.</given-names></name> <name><surname>Yu</surname> <given-names>D.</given-names></name> <name><surname>Xu</surname> <given-names>Y.</given-names></name> <name><surname>Nakigozi</surname> <given-names>G.</given-names></name> <name><surname>Nakasujja</surname> <given-names>N.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Immunometabolic reprogramming in response to HIV infection is not fully normalized by suppressive antiretroviral therapy</article-title>. <source>Viruses</source> <volume>14</volume>:<fpage>1313</fpage>. doi: <pub-id pub-id-type="doi">10.3390/v14061313</pub-id>, PMID: <pub-id pub-id-type="pmid">35746785</pub-id></citation></ref>
<ref id="ref13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dickens</surname> <given-names>A. M.</given-names></name> <name><surname>Anthony</surname> <given-names>D. C.</given-names></name> <name><surname>Deutsch</surname> <given-names>R.</given-names></name> <name><surname>Mielke</surname> <given-names>M. M.</given-names></name> <name><surname>Claridge</surname> <given-names>T. D.</given-names></name> <name><surname>Grant</surname> <given-names>I.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Cerebrospinal fluid metabolomics implicate bioenergetic adaptation as a neural mechanism regulating shifts in cognitive states of HIV-infected patients</article-title>. <source>AIDS</source> <volume>29</volume>, <fpage>559</fpage>&#x2013;<lpage>569</lpage>. doi: <pub-id pub-id-type="doi">10.1097/QAD.0000000000000580</pub-id>, PMID: <pub-id pub-id-type="pmid">25611149</pub-id></citation></ref>
<ref id="ref14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ernst</surname> <given-names>T.</given-names></name> <name><surname>Chang</surname> <given-names>L.</given-names></name> <name><surname>Arnold</surname> <given-names>S.</given-names></name></person-group> (<year>2003</year>). <article-title>Increased glial metabolites predict increased working memory network activation in HIV brain injury</article-title>. <source>NeuroImage</source> <volume>19</volume>, <fpage>1686</fpage>&#x2013;<lpage>1693</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1053-8119(03)00232-5</pub-id>, PMID: <pub-id pub-id-type="pmid">12948723</pub-id></citation></ref>
<ref id="ref15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname> <given-names>S. K.</given-names></name> <name><surname>Novak</surname> <given-names>J. E.</given-names></name> <name><surname>Agranoff</surname> <given-names>B. W.</given-names></name></person-group> (<year>2002</year>). <article-title>Inositol and higher inositol phosphates in neural tissues: homeostasis, metabolism and functional significance</article-title>. <source>J. Neurochem.</source> <volume>82</volume>, <fpage>736</fpage>&#x2013;<lpage>754</lpage>. doi: <pub-id pub-id-type="doi">10.1046/j.1471-4159.2002.01041.x</pub-id>, PMID: <pub-id pub-id-type="pmid">12358779</pub-id></citation></ref>
<ref id="ref16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Rodriguez</surname> <given-names>D.</given-names></name> <name><surname>Gimenez-Cassina</surname> <given-names>A.</given-names></name></person-group> (<year>2021</year>). <article-title>Ketone bodies in the brain beyond fuel metabolism: from excitability to gene expression and cell signaling</article-title>. <source>Front. Mol. Neurosci.</source> <volume>14</volume>:<fpage>732120</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnmol.2021.732120</pub-id>, PMID: <pub-id pub-id-type="pmid">34512261</pub-id></citation></ref>
<ref id="ref17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gleichmann</surname> <given-names>M.</given-names></name> <name><surname>Mattson</surname> <given-names>M. P.</given-names></name></person-group> (<year>2011</year>). <article-title>Neuronal calcium homeostasis and dysregulation</article-title>. <source>Antioxid. Redox Signal.</source> <volume>14</volume>, <fpage>1261</fpage>&#x2013;<lpage>1273</lpage>. doi: <pub-id pub-id-type="doi">10.1089/ars.2010.3386</pub-id>, PMID: <pub-id pub-id-type="pmid">20626318</pub-id></citation></ref>
<ref id="ref18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gonz&#x00E1;lez-Scarano</surname> <given-names>F.</given-names></name> <name><surname>Mart&#x00ED;n-Garc&#x00ED;a</surname> <given-names>J.</given-names></name></person-group> (<year>2005</year>). <article-title>The neuropathogenesis of AIDS</article-title>. <source>Nat. Rev. Immunol.</source> <volume>5</volume>, <fpage>69</fpage>&#x2013;<lpage>81</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nri1527</pub-id></citation></ref>
<ref id="ref19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Green</surname> <given-names>M. V.</given-names></name> <name><surname>Raybuck</surname> <given-names>J. D.</given-names></name> <name><surname>Zhang</surname> <given-names>X.</given-names></name> <name><surname>Wu</surname> <given-names>M. M.</given-names></name> <name><surname>Thayer</surname> <given-names>S. A.</given-names></name></person-group> (<year>2019</year>). <article-title>Scaling synapses in the presence of HIV</article-title>. <source>Neurochem. Res.</source> <volume>44</volume>, <fpage>234</fpage>&#x2013;<lpage>246</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11064-018-2502-2</pub-id>, PMID: <pub-id pub-id-type="pmid">29541929</pub-id></citation></ref>
<ref id="ref20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harezlak</surname> <given-names>J.</given-names></name> <name><surname>Buchthal</surname> <given-names>S.</given-names></name> <name><surname>Taylor</surname> <given-names>M.</given-names></name> <name><surname>Schifitto</surname> <given-names>G.</given-names></name> <name><surname>Zhong</surname> <given-names>J.</given-names></name> <name><surname>Daar</surname> <given-names>E.</given-names></name> <etal/></person-group>. (<year>2011</year>). <article-title>Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment</article-title>. <source>AIDS</source> <volume>25</volume>, <fpage>625</fpage>&#x2013;<lpage>633</lpage>. doi: <pub-id pub-id-type="doi">10.1097/QAD.0b013e3283427da7</pub-id>, PMID: <pub-id pub-id-type="pmid">21297425</pub-id></citation></ref>
<ref id="ref21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hui</surname> <given-names>L.</given-names></name> <name><surname>Chen</surname> <given-names>X.</given-names></name> <name><surname>Bhatt</surname> <given-names>D.</given-names></name> <name><surname>Geiger</surname> <given-names>N. H.</given-names></name> <name><surname>Rosenberger</surname> <given-names>T. A.</given-names></name> <name><surname>Haughey</surname> <given-names>N. J.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Ketone bodies protection against HIV-1 tat-induced neurotoxicity</article-title>. <source>J. Neurochem.</source> <volume>122</volume>, <fpage>382</fpage>&#x2013;<lpage>391</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1471-4159.2012.07764.x</pub-id>, PMID: <pub-id pub-id-type="pmid">22524563</pub-id></citation></ref>
<ref id="ref22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Irollo</surname> <given-names>E.</given-names></name> <name><surname>Luchetta</surname> <given-names>J.</given-names></name> <name><surname>Ho</surname> <given-names>C.</given-names></name> <name><surname>Nash</surname> <given-names>B.</given-names></name> <name><surname>Meucci</surname> <given-names>O.</given-names></name></person-group> (<year>2021</year>). <article-title>Mechanisms of neuronal dysfunction in HIV-associated neurocognitive disorders</article-title>. <source>Cell. Mol. Life Sci.</source> <volume>78</volume>, <fpage>4283</fpage>&#x2013;<lpage>4303</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00018-021-03785-y</pub-id>, PMID: <pub-id pub-id-type="pmid">33585975</pub-id></citation></ref>
<ref id="ref24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaur</surname> <given-names>S. U.</given-names></name> <name><surname>Oyeyemi</surname> <given-names>B. F.</given-names></name> <name><surname>Shet</surname> <given-names>A.</given-names></name> <name><surname>Gopalan</surname> <given-names>B. P.</given-names></name> <name><surname>Himanshu</surname> <given-names>D.</given-names></name> <name><surname>Bhavesh</surname> <given-names>N. S.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Plasma metabolomic study in perinatally HIV-infected children using 1H NMR spectroscopy reveals perturbed metabolites that sustain during therapy</article-title>. <source>PLoS One</source> <volume>15</volume>:<fpage>e0238316</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0238316</pub-id>, PMID: <pub-id pub-id-type="pmid">32866201</pub-id></citation></ref>
<ref id="ref25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Keram</surname> <given-names>A.</given-names></name> <name><surname>Pei</surname> <given-names>N.</given-names></name> <name><surname>Qi</surname> <given-names>T.</given-names></name> <name><surname>Xun</surname> <given-names>J.</given-names></name> <name><surname>Gu</surname> <given-names>Y.</given-names></name> <name><surname>Li</surname> <given-names>W.</given-names></name></person-group> (<year>2021</year>). <article-title>Untargeted GC/TOFMS unravel metabolic profiles in cerebrospinal fluid of Chinese people living with HIV</article-title>. <source>J. Clin. Lab. Anal.</source> <volume>35</volume>:<fpage>e23673</fpage>. doi: <pub-id pub-id-type="doi">10.1002/jcla.23673</pub-id>, PMID: <pub-id pub-id-type="pmid">33476447</pub-id></citation></ref>
<ref id="ref26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>D. Y.</given-names></name> <name><surname>Vallejo</surname> <given-names>J.</given-names></name> <name><surname>Rho</surname> <given-names>J. M.</given-names></name></person-group> (<year>2010</year>). <article-title>Ketones prevent synaptic dysfunction induced by mitochondrial respiratory complex inhibitors</article-title>. <source>J. Neurochem.</source> <volume>114</volume>, <fpage>130</fpage>&#x2013;<lpage>141</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1471-4159.2010.06728.x</pub-id></citation></ref>
<ref id="ref27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kulkarni</surname> <given-names>M. M.</given-names></name> <name><surname>Ratcliff</surname> <given-names>A. N.</given-names></name> <name><surname>Bhat</surname> <given-names>M.</given-names></name> <name><surname>Alwarawrah</surname> <given-names>Y.</given-names></name> <name><surname>Hughes</surname> <given-names>P.</given-names></name> <name><surname>Arcos</surname> <given-names>J.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Cellular fatty acid synthase is required for late stages of HIV-1 replication</article-title>. <source>Retrovirology</source> <volume>14</volume>:<fpage>45</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12977-017-0368-z</pub-id>, PMID: <pub-id pub-id-type="pmid">28962653</pub-id></citation></ref>
<ref id="ref28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lang</surname> <given-names>F.</given-names></name> <name><surname>Busch</surname> <given-names>G. L.</given-names></name> <name><surname>Ritter</surname> <given-names>M.</given-names></name> <name><surname>Volkl</surname> <given-names>H.</given-names></name> <name><surname>Waldegger</surname> <given-names>S.</given-names></name> <name><surname>Gulbins</surname> <given-names>E.</given-names></name> <etal/></person-group>. (<year>1998</year>). <article-title>Functional significance of cell volume regulatory mechanisms</article-title>. <source>Physiol. Rev.</source> <volume>78</volume>, <fpage>247</fpage>&#x2013;<lpage>306</lpage>. doi: <pub-id pub-id-type="doi">10.1152/physrev.1998.78.1.247</pub-id></citation></ref>
<ref id="ref29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Legault</surname> <given-names>J. T.</given-names></name> <name><surname>Strittmatter</surname> <given-names>L.</given-names></name> <name><surname>Tardif</surname> <given-names>J.</given-names></name> <name><surname>Sharma</surname> <given-names>R.</given-names></name> <name><surname>Tremblay-Vaillancourt</surname> <given-names>V.</given-names></name> <name><surname>Aubut</surname> <given-names>C.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>A metabolic signature of mitochondrial dysfunction revealed through a monogenic form of Leigh syndrome</article-title>. <source>Cell Rep.</source> <volume>13</volume>, <fpage>981</fpage>&#x2013;<lpage>989</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.celrep.2015.09.054</pub-id></citation></ref>
<ref id="ref30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lertratanangkoon</surname> <given-names>K.</given-names></name> <name><surname>Orkiszewski</surname> <given-names>R. S.</given-names></name> <name><surname>Scimeca</surname> <given-names>J. M.</given-names></name></person-group> (<year>1996</year>). <article-title>Methyl-donor deficiency due to chemically induced glutathione depletion</article-title>. <source>Cancer Res.</source> <volume>56</volume>, <fpage>995</fpage>&#x2013;<lpage>1005</lpage>, PMID: <pub-id pub-id-type="pmid">8640792</pub-id></citation></ref>
<ref id="ref31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Madeira</surname> <given-names>C.</given-names></name> <name><surname>Vargas-Lopes</surname> <given-names>C.</given-names></name> <name><surname>Brandao</surname> <given-names>C. O.</given-names></name> <name><surname>Reis</surname> <given-names>T.</given-names></name> <name><surname>Laks</surname> <given-names>J.</given-names></name> <name><surname>Panizzutti</surname> <given-names>R.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Elevated glutamate and glutamine levels in the cerebrospinal fluid of patients with probable Alzheimer's disease and depression</article-title>. <source>Front. Psych.</source> <volume>9</volume>:<fpage>561</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fpsyt.2018.00561</pub-id></citation></ref>
<ref id="ref32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Magistretti</surname> <given-names>P. J.</given-names></name> <name><surname>Allaman</surname> <given-names>I.</given-names></name></person-group> (<year>2018</year>). <article-title>Lactate in the brain: from metabolic end-product to signalling molecule</article-title>. <source>Nat. Rev. Neurosci.</source> <volume>19</volume>, <fpage>235</fpage>&#x2013;<lpage>249</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrn.2018.19</pub-id>, PMID: <pub-id pub-id-type="pmid">29515192</pub-id></citation></ref>
<ref id="ref33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mason</surname> <given-names>S.</given-names></name></person-group> (<year>2017</year>). <article-title>Lactate shuttles in neuroenergetics &#x2013; homeostasis, allostasis and beyond</article-title>. <source>Front. Neurosci.</source> <volume>11</volume>:<fpage>43</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnins.2017.00043</pub-id></citation></ref>
<ref id="ref34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McArthur</surname> <given-names>J. C.</given-names></name> <name><surname>Johnson</surname> <given-names>T. P.</given-names></name></person-group> (<year>2020</year>). <article-title>Chronic inflammation mediates brain injury in HIV infection: relevance for cure strategies</article-title>. <source>Curr. Opin. Neurol.</source> <volume>33</volume>, <fpage>397</fpage>&#x2013;<lpage>404</lpage>. doi: <pub-id pub-id-type="doi">10.1097/WCO.0000000000000807</pub-id>, PMID: <pub-id pub-id-type="pmid">32209807</pub-id></citation></ref>
<ref id="ref35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Monsorno</surname> <given-names>K.</given-names></name> <name><surname>Buckinx</surname> <given-names>A.</given-names></name> <name><surname>Paolicelli</surname> <given-names>R. C.</given-names></name></person-group> (<year>2022</year>). <article-title>Microglial metabolic flexibility: emerging roles for lactate</article-title>. <source>Trends Endocrinol. Metab.</source> <volume>33</volume>, <fpage>186</fpage>&#x2013;<lpage>195</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tem.2021.12.001</pub-id></citation></ref>
<ref id="ref36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname> <given-names>J. C.</given-names></name> <name><surname>Verdin</surname> <given-names>E.</given-names></name></person-group> (<year>2017</year>). <article-title>Beta-hydroxybutyrate: a signaling metabolite</article-title>. <source>Ann. Rev. Nutr.</source> <volume>37</volume>, <fpage>51</fpage>&#x2013;<lpage>76</lpage>. doi: <pub-id pub-id-type="doi">10.1146/annurev-nutr-071816-064916</pub-id>, PMID: <pub-id pub-id-type="pmid">28826372</pub-id></citation></ref>
<ref id="ref37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oswald</surname> <given-names>M. C. W.</given-names></name> <name><surname>Garnham</surname> <given-names>N.</given-names></name> <name><surname>Sweeney</surname> <given-names>S. T.</given-names></name> <name><surname>Landgraf</surname> <given-names>M.</given-names></name></person-group> (<year>2018</year>). <article-title>Regulation of neuronal development and function by ROS</article-title>. <source>FEBS Lett.</source> <volume>592</volume>, <fpage>679</fpage>&#x2013;<lpage>691</lpage>. doi: <pub-id pub-id-type="doi">10.1002/1873-3468.12972</pub-id>, PMID: <pub-id pub-id-type="pmid">29323696</pub-id></citation></ref>
<ref id="ref38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oyarz&#x00E1;bal</surname> <given-names>A.</given-names></name> <name><surname>Musokhranova</surname> <given-names>U.</given-names></name> <name><surname>Barros</surname> <given-names>L. F.</given-names></name> <name><surname>Garc&#x00ED;a-Cazorla</surname> <given-names>A.</given-names></name></person-group> (<year>2021</year>). <article-title>Energy metabolism in childhood neurodevelopmental disorders</article-title>. <source>EBioMedicine</source> <volume>69</volume>:<fpage>103474</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ebiom.2021.103474</pub-id></citation></ref>
<ref id="ref39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pajkrt</surname> <given-names>D.</given-names></name> <name><surname>Blokhuis</surname> <given-names>C.</given-names></name> <name><surname>Caan</surname> <given-names>M.</given-names></name> <name><surname>Kootstra</surname> <given-names>N.</given-names></name></person-group> (<year>2016</year>). <article-title>Neurodevelopmental delay in pediatric HIV/AIDS: current perspectives</article-title>. <source>Neurobehav. HIV Med.</source> <volume>7</volume>, <fpage>1</fpage>&#x2013;<lpage>13</lpage>. doi: <pub-id pub-id-type="doi">10.2147/NBHIV.S68954</pub-id></citation></ref>
<ref id="ref40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Palmer</surname> <given-names>C. S.</given-names></name> <name><surname>Cherry</surname> <given-names>C. L.</given-names></name> <name><surname>Sada-Ovalle</surname> <given-names>I.</given-names></name> <name><surname>Singh</surname> <given-names>A.</given-names></name> <name><surname>Crowe</surname> <given-names>S. M.</given-names></name></person-group> (<year>2016</year>). <article-title>Glucose metabolism in T cells and monocytes: new perspectives in HIV pathogenesis</article-title>. <source>EBioMedicine</source> <volume>6</volume>, <fpage>31</fpage>&#x2013;<lpage>41</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ebiom.2016.02.012</pub-id>, PMID: <pub-id pub-id-type="pmid">27211546</pub-id></citation></ref>
<ref id="ref41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pellerin</surname> <given-names>L.</given-names></name></person-group> (<year>2010</year>). <article-title>Food for thought: the importance of glucose and other energy substrates for sustaining brain function under varying levels of activity</article-title>. <source>Diabetes Metab.</source> <volume>36</volume>, <fpage>S59</fpage>&#x2013;<lpage>S63</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1262-3636(10)70469-9</pub-id></citation></ref>
<ref id="ref42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perl</surname> <given-names>A.</given-names></name> <name><surname>Banki</surname> <given-names>K.</given-names></name></person-group> (<year>2004</year>). <article-title>Genetic and metabolic control of the mitochondrial transmembrane potential and reactive oxygen intermediate production in HIV disease</article-title>. <source>Antioxid. Redox Signal.</source> <volume>2004</volume>, <fpage>551</fpage>&#x2013;<lpage>573</lpage>. doi: <pub-id pub-id-type="doi">10.1089/15230860050192323</pub-id></citation></ref>
<ref id="ref43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Porcheray</surname> <given-names>F.</given-names></name> <name><surname>Leone</surname> <given-names>C.</given-names></name> <name><surname>Samah</surname> <given-names>B.</given-names></name> <name><surname>Rimaniol</surname> <given-names>A. C.</given-names></name> <name><surname>Dereuddre-Bosquet</surname> <given-names>N.</given-names></name> <name><surname>Gras</surname> <given-names>G.</given-names></name></person-group> (<year>2006</year>). <article-title>Glutamate metabolism in HIV-infected macrophages: implications for the CNS</article-title>. <source>Am. J. Physiol. Cell Physiol.</source> <volume>291</volume>, <fpage>C618</fpage>&#x2013;<lpage>C626</lpage>. doi: <pub-id pub-id-type="doi">10.1152/ajpcell.00021.2006</pub-id></citation></ref>
<ref id="ref44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Puchades-Carrasco</surname> <given-names>L.</given-names></name> <name><surname>Palomino-Schatzlein</surname> <given-names>M.</given-names></name> <name><surname>Perez-Rambla</surname> <given-names>C.</given-names></name> <name><surname>Pineda-Lucena</surname> <given-names>A.</given-names></name></person-group> (<year>2016</year>). <article-title>Bioinformatics tools for the analysis of NMR metabolomics studies focused on the identification of clinically relevant biomarkers</article-title>. <source>Brief. Bioinform.</source> <volume>17</volume>, <fpage>541</fpage>&#x2013;<lpage>552</lpage>. doi: <pub-id pub-id-type="doi">10.1093/bib/bbv077</pub-id>, PMID: <pub-id pub-id-type="pmid">26342127</pub-id></citation></ref>
<ref id="ref45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruddick</surname> <given-names>J. A.</given-names></name></person-group> (<year>1972</year>). <article-title>Toxicology, metabolism, and biochemistry of 1,2-propanediol</article-title>. <source>Toxicol. Appl. Pharmacol.</source> <volume>21</volume>, <fpage>102</fpage>&#x2013;<lpage>111</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0041-008X(72)90032-4</pub-id>, PMID: <pub-id pub-id-type="pmid">4553872</pub-id></citation></ref>
<ref id="ref46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sailasuta</surname> <given-names>N.</given-names></name> <name><surname>Ananworanich</surname> <given-names>J.</given-names></name> <name><surname>Lerdlum</surname> <given-names>S.</given-names></name> <name><surname>Sithinamsuwan</surname> <given-names>P.</given-names></name> <name><surname>Fletcher</surname> <given-names>J. L.</given-names></name> <name><surname>Tipsuk</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Neuronal-glia markers by magnetic resonance spectroscopy in HIV before and after combination antiretroviral therapy</article-title>. <source>J. Acquir. Immune Defic. Syndr.</source> <volume>71</volume>, <fpage>24</fpage>&#x2013;<lpage>30</lpage>. doi: <pub-id pub-id-type="doi">10.1097/QAI.0000000000000779</pub-id>, PMID: <pub-id pub-id-type="pmid">26258565</pub-id></citation></ref>
<ref id="ref47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname> <given-names>L.</given-names></name> <name><surname>Major</surname> <given-names>E.</given-names></name></person-group> (<year>2006</year>). <article-title>Neural progenitors and HIV-1- associated central nervous system disease in adults and children</article-title>. <source>Curr. HIV Res.</source> <volume>4</volume>, <fpage>319</fpage>&#x2013;<lpage>327</lpage>. doi: <pub-id pub-id-type="doi">10.2174/157016206777709438</pub-id>, PMID: <pub-id pub-id-type="pmid">16842084</pub-id></citation></ref>
<ref id="ref48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shehata</surname> <given-names>H. M.</given-names></name> <name><surname>Murphy</surname> <given-names>A. J.</given-names></name> <name><surname>Sam Lee</surname> <given-names>S. K.</given-names></name></person-group> (<year>2017</year>). <article-title>Sugar or fat? - metabolic requirements for immunity to viral infections</article-title>. <source>Front. Immunol.</source> <volume>8</volume>:<fpage>1311</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2017.01311</pub-id>, PMID: <pub-id pub-id-type="pmid">29085369</pub-id></citation></ref>
<ref id="ref49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sinharay</surname> <given-names>S.</given-names></name> <name><surname>Hammoud</surname> <given-names>D. A.</given-names></name></person-group> (<year>2019</year>). <article-title>Brain PET imaging: value for understanding the pathophysiology of HIV-associated neurocognitive disorder (HAND)</article-title>. <source>Curr. HIV/AIDS Rep.</source> <volume>16</volume>, <fpage>66</fpage>&#x2013;<lpage>75</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11904-019-00419-8</pub-id>, PMID: <pub-id pub-id-type="pmid">30778853</pub-id></citation></ref>
<ref id="ref50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname> <given-names>R.</given-names></name> <name><surname>Wilkins</surname> <given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>Perinatally acquired HIV infection: long-term neuropsychological consequences and challenges ahead</article-title>. <source>Child Neuropsychol.</source> <volume>21</volume>, <fpage>234</fpage>&#x2013;<lpage>268</lpage>. doi: <pub-id pub-id-type="doi">10.1080/09297049.2014.898744</pub-id>, PMID: <pub-id pub-id-type="pmid">24697320</pub-id></citation></ref>
<ref id="ref51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Solomons</surname> <given-names>R. S.</given-names></name> <name><surname>Visser</surname> <given-names>D. H.</given-names></name> <name><surname>Marais</surname> <given-names>B. J.</given-names></name> <name><surname>Schoeman</surname> <given-names>J. F.</given-names></name> <name><surname>van Furth</surname> <given-names>A. M.</given-names></name></person-group> (<year>2016</year>). <article-title>Diagnostic accuracy of a uniform research case definition for TBM in children: a prospective study</article-title>. <source>Int. J. Tuberc. Lung Dis.</source> <volume>7</volume>, <fpage>903</fpage>&#x2013;<lpage>908</lpage>. doi: <pub-id pub-id-type="doi">10.5588/ijtld.15.0509</pub-id></citation></ref>
<ref id="ref52"><citation citation-type="book"><person-group person-group-type="author"><collab id="coll111">UNAIDS Global AIDS Update</collab></person-group> (<year>2022</year>). <source>In Danger: UNAIDS Global AIDS Update 2022</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>Joint United Nations Programme on HIV/AIDS</publisher-name> Licence: CC BY-NC-SA 3.0 IGO.</citation></ref>
<ref id="ref53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Zyl</surname> <given-names>C. D. W.</given-names></name> <name><surname>Loots</surname> <given-names>D. T.</given-names></name> <name><surname>Solomons</surname> <given-names>R.</given-names></name> <name><surname>Van Reenen</surname> <given-names>M.</given-names></name> <name><surname>Mason</surname> <given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>Metabolic characterization of tuberculous meningitis in a south African paediatric population using 1 H NMR metabolomics</article-title>. <source>J. Infect.</source> <volume>81</volume>, <fpage>743</fpage>&#x2013;<lpage>752</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jinf.2020.06.078</pub-id>, PMID: <pub-id pub-id-type="pmid">32712206</pub-id></citation></ref>
<ref id="ref54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vazquez-Santiago</surname> <given-names>F. J.</given-names></name> <name><surname>Noel</surname> <given-names>R. J.</given-names></name> <name><surname>Porter</surname> <given-names>J. T.</given-names></name> <name><surname>Rivera-Amill</surname> <given-names>V.</given-names></name></person-group> (<year>2014</year>). <article-title>Glutamate metabolism and HIV-associated neurocognitive disorders</article-title>. <source>J. Neurovirol.</source> <volume>20</volume>, <fpage>315</fpage>&#x2013;<lpage>331</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s13365-014-0258-2</pub-id>, PMID: <pub-id pub-id-type="pmid">24867611</pub-id></citation></ref>
<ref id="ref55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Westerhuis</surname> <given-names>J. A.</given-names></name> <name><surname>Hoefsloot</surname> <given-names>H. C.</given-names></name> <name><surname>Smit</surname> <given-names>S.</given-names></name> <name><surname>Vis</surname> <given-names>D. J.</given-names></name> <name><surname>Smilde</surname> <given-names>A. K.</given-names></name> <name><surname>van Velzen</surname> <given-names>E. J.</given-names></name> <etal/></person-group>. (<year>2008</year>). <article-title>Assessment of PLSDA cross validation</article-title>. <source>Metabolomics</source> <volume>4</volume>, <fpage>81</fpage>&#x2013;<lpage>89</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11306-007-0099-6</pub-id></citation></ref>
<ref id="ref56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname> <given-names>M. E.</given-names></name> <name><surname>Janse Van Rensburg</surname> <given-names>A.</given-names></name> <name><surname>Loots</surname> <given-names>D. T.</given-names></name> <name><surname>Naud&#x00E9;</surname> <given-names>P. J. W.</given-names></name> <name><surname>Mason</surname> <given-names>S.</given-names></name></person-group> (<year>2021b</year>). <article-title>Immune dysregulation is associated with neurodevelopment and neurocognitive performance in HIV pediatric populations &#x2013; a scoping review</article-title>. <source>Viruses</source> <volume>13</volume>:<fpage>2543</fpage>. doi: <pub-id pub-id-type="doi">10.3390/v13122543</pub-id>, PMID: <pub-id pub-id-type="pmid">34960812</pub-id></citation></ref>
<ref id="ref57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname> <given-names>M. E.</given-names></name> <name><surname>Naude</surname> <given-names>P. J. W.</given-names></name> <name><surname>van der Westhuizen</surname> <given-names>F. H.</given-names></name></person-group> (<year>2021a</year>). <article-title>Proteomics and metabolomics of HIV-associated neurocognitive disorders: a systematic review</article-title>. <source>J. Neurochem.</source> <volume>157</volume>, <fpage>429</fpage>&#x2013;<lpage>449</lpage>. doi: <pub-id pub-id-type="doi">10.1111/jnc.15295</pub-id>, PMID: <pub-id pub-id-type="pmid">33421125</pub-id></citation></ref>
<ref id="ref58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>C.</given-names></name> <name><surname>Sun</surname> <given-names>D.</given-names></name></person-group> (<year>2015</year>). <article-title>GABA receptors in brain development, function, and injury</article-title>. <source>Metab. Brain Dis.</source> <volume>30</volume>, <fpage>367</fpage>&#x2013;<lpage>379</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11011-014-9560-1</pub-id>, PMID: <pub-id pub-id-type="pmid">24820774</pub-id></citation></ref>
<ref id="ref59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yadav</surname> <given-names>S. K.</given-names></name> <name><surname>Gupta</surname> <given-names>R. K.</given-names></name> <name><surname>Garg</surname> <given-names>R. K.</given-names></name> <name><surname>Venkatesh</surname> <given-names>V.</given-names></name> <name><surname>Gupta</surname> <given-names>P. K.</given-names></name> <name><surname>Singh</surname> <given-names>A. K.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Altered structural brain changes and neurocognitive performance in pediatric HIV</article-title>. <source>NeuroImage</source> <volume>14</volume>, <fpage>316</fpage>&#x2013;<lpage>322</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.nicl.2017.01.032</pub-id>, PMID: <pub-id pub-id-type="pmid">28224079</pub-id></citation></ref>
<ref id="ref60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>L.</given-names></name> <name><surname>Diefenbach</surname> <given-names>E.</given-names></name> <name><surname>Crossett</surname> <given-names>B.</given-names></name> <name><surname>Tran</surname> <given-names>S. L.</given-names></name> <name><surname>Ng</surname> <given-names>T.</given-names></name> <name><surname>Rizos</surname> <given-names>H.</given-names></name> <etal/></person-group>. (<year>2010</year>). <article-title>First evidence of overlaps between HIV-associated dementia (HAD) and non-viral neurodegenerative diseases: proteomic analysis of the frontal cortex from HIV+ patients with and without dementia</article-title>. <source>Mol. Neurodegener.</source> <volume>5</volume>:<fpage>27</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1750-1326-5-27</pub-id>, PMID: <pub-id pub-id-type="pmid">20573273</pub-id></citation></ref>
</ref-list>
</back>
</article>